,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,357,2,1,,11110784,2157,Inactive,,,,,AP1 Signaling Pathway,Confirmatory,,
1,357,2,1,,11110785,2157,Inactive,,,,,AP1 Signaling Pathway,Confirmatory,,
2,410,1,5,,11110784,2157,Active,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
3,410,1,5,,11110785,2157,Active,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
4,411,2,1,,11110784,2157,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
5,411,2,1,,11110785,2157,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
6,444,1,1,,11110784,2157,Inconclusive,,,,,NFAT Signaling Pathway,Confirmatory,,
7,444,1,1,,11110785,2157,Inactive,,,,,NFAT Signaling Pathway,Confirmatory,,
8,445,3,1,,11110784,2157,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
9,445,3,1,,11110785,2157,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
10,446,1,1,,11110784,2157,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
11,446,1,1,,11110785,2157,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
12,447,1,1,,11110784,2157,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
13,447,1,1,,11110785,2157,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
14,448,1,2,,11110784,2157,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
15,448,1,2,,11110785,2157,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
16,450,1,2,,11110784,2157,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
17,450,1,2,,11110785,2157,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
18,451,1,2,,11110784,2157,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
19,451,1,2,,11110785,2157,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
20,526,1,1,,11110784,2157,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
21,526,1,1,,11110785,2157,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
22,530,1,1,,11110784,2157,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
23,530,1,1,,11110785,2157,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
24,584,1,3,,11110784,2157,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
25,584,1,3,,11110785,2157,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
26,585,1,4,,11110784,2157,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
27,585,1,4,,11110785,2157,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
28,587,1,5,,11110784,2157,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
29,587,1,5,,11110785,2157,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
30,588,1,4,,11110784,2157,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
31,588,1,4,,11110785,2157,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
32,589,1,3,,11110784,2157,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
33,589,1,3,,11110785,2157,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
34,590,1,3,,11110784,2157,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
35,590,1,3,,11110785,2157,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
36,591,1,4,,11110784,2157,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
37,591,1,4,,11110785,2157,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
38,592,1,6,,11110784,2157,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
39,592,1,6,,11110785,2157,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
40,593,1,4,,11110784,2157,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
41,593,1,4,,11110785,2157,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
42,594,1,4,,11110784,2157,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
43,594,1,4,,11110785,2157,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
44,595,1,3,,11110784,2157,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
45,595,1,3,,11110785,2157,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
46,596,1,2,,11110784,2157,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
47,596,1,2,,11110785,2157,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
48,597,1,3,,11110784,2157,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
49,597,1,3,,11110785,2157,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
50,603,1,2,,11110784,2157,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
51,603,1,2,,11110785,2157,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
52,605,1,2,,11110784,2157,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
53,605,1,2,,11110785,2157,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
54,607,1,3,,11110784,2157,Inconclusive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
55,607,1,3,,11110785,2157,Inconclusive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
56,662,1,1,,11110784,2157,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
57,662,1,1,,11110785,2157,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
58,875,1,2,,11110784,2157,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
59,875,1,2,,11110785,2157,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
60,879,1,2,,11110784,2157,Inactive,3290016.0,6002.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
61,879,1,2,,11110784,2157,Inactive,33946324.0,2770.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
62,880,2,1,,11110785,2157,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
63,880,2,1,,11110785,2157,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
64,880,2,1,,26751596,2157,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
65,880,2,1,,26751596,2157,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
66,880,2,1,,26751597,2157,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
67,880,2,1,,26751597,2157,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
68,881,2,2,,11110784,2157,Inactive,317373425.0,247.0,7.9433,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
69,881,2,2,,11110785,2157,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
70,883,1,3,,11110784,2157,Inconclusive,13699818.0,1559.0,0.0631,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
71,883,1,3,,11110785,2157,Inconclusive,13699818.0,1559.0,0.0079,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
72,884,1,2,,11110784,2157,Inactive,13435386.0,1576.0,6.3096,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
73,884,1,2,,11110785,2157,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
74,885,1,2,,11110784,2157,Inconclusive,13435386.0,1576.0,6.3096,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
75,885,1,2,,11110785,2157,Inactive,13435386.0,1576.0,,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
76,886,1,2,,11110784,2157,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
77,886,1,2,,11110784,2157,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
78,886,1,2,,11110785,2157,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
79,886,1,2,,11110785,2157,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
80,887,1,2,,11110784,2157,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
81,887,1,2,,11110785,2157,Inactive,1832253.0,246.0,,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
82,889,1,3,,11110784,2157,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
83,889,1,3,,11110785,2157,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
84,891,1,2,,11110784,2157,Active,40805836.0,1565.0,31.6228,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
85,891,1,2,,11110785,2157,Inactive,40805836.0,1565.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
86,892,1,2,,11110784,2157,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
87,892,1,2,,11110785,2157,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
88,893,1,2,,11110784,2157,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
89,893,1,2,,11110784,2157,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
90,893,1,2,,11110785,2157,Inactive,122921310.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
91,893,1,2,,11110785,2157,Inactive,122921311.0,,,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
92,894,2,1,,11110785,2157,Inactive,31542939.0,3248.0,,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
93,895,1,2,,11110784,2157,Inconclusive,21620132.0,4790.0,3.5481,Potency,qHTS Assay for Identification of Small Molecule Antagonists for NFkB Signaling Pathway,Confirmatory,,
94,899,1,2,,11110784,2157,Inactive,4503219.0,1557.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
95,899,1,2,,11110785,2157,Inactive,4503219.0,1557.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
96,900,1,3,,11110784,2157,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
97,900,1,3,,11110785,2157,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
98,901,1,2,,11110784,2157,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
99,901,1,2,,11110785,2157,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
100,902,1,2,,11110784,2157,Inconclusive,120407068.0,7157.0,10.0,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
101,902,1,2,,11110785,2157,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
102,912,1,2,,11110784,2157,Inconclusive,21392848.0,,15.8489,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
103,912,1,2,,11110785,2157,Inactive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
104,914,1,3,,11110784,2157,Inconclusive,32879895.0,3091.0,31.6228,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
105,914,1,3,,11110785,2157,Inconclusive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
106,915,1,3,,11110784,2157,Inconclusive,32879895.0,3091.0,31.6228,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
107,915,1,3,,11110785,2157,Inconclusive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
108,917,1,3,,11110784,2157,Inconclusive,120660324.0,7066.0,25.1189,Potency,qHTS Assay for Identification of Small Molecule Agonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
109,918,1,3,,11110784,2157,Inconclusive,120660324.0,7066.0,25.1189,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
110,923,1,2,,11110784,2157,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
111,923,1,2,,11110785,2157,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
112,924,1,2,,11110784,2157,Inconclusive,120407068.0,7157.0,10.0,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
113,924,1,2,,11110785,2157,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
114,925,1,2,,11110784,2157,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
115,925,1,2,,11110785,2157,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
116,926,1,2,,11110784,2157,Inconclusive,38016895.0,7253.0,6.3096,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
117,926,1,2,,11110785,2157,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
118,927,1,3,,11110784,2157,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
119,927,1,3,,11110785,2157,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
120,928,1,2,,11110784,2157,Inconclusive,21620132.0,4790.0,3.5481,Potency,qHTS Assay for Identification of Small Molecule Agonists for NFkB Signaling Pathway,Confirmatory,,
121,938,1,2,,11110784,2157,Inconclusive,38016895.0,7253.0,6.3096,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
122,938,1,2,,11110785,2157,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
123,943,1,2,,11110784,2157,Inconclusive,18249941.0,25229.0,17.7828,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Kinetic Measurement of Intracellular Calcium Response,Confirmatory,,
124,944,1,2,,11110784,2157,Inactive,18249941.0,25229.0,,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Measurement of IP-One Response,Confirmatory,,
125,945,1,4,,11110784,2157,Inactive,290753097.0,,,Potency,qHTS Validation Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
126,954,1,2,,11110784,2157,Inactive,33286420.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle Pyruvate Kinase,Confirmatory,,
127,957,1,2,,11110784,2157,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 4.5,Confirmatory,,
128,958,1,2,,11110784,2157,Inactive,33286420.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle Pyruvate Kinase,Confirmatory,,
129,959,1,4,,11110784,2157,Inactive,290753097.0,,,Potency,qHTS Validation Assay for Activators of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
130,992,1,3,,11110784,2157,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Human alpha-Galactosidase at pH 4.5,Confirmatory,,
131,995,1,2,,11110784,2157,Inconclusive,66932916.0,5594.0,10.0,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
132,995,1,2,,11110785,2157,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
133,997,1,2,,11110784,2157,Inactive,52076901.0,4341833.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Rice alpha-Glucosidase at pH 5.0,Confirmatory,,
134,998,1,2,,11110784,2157,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 5.9,Confirmatory,,
135,1030,2,1,,11110785,2157,Inconclusive,30582681.0,216.0,5.0119,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
136,1030,2,1,,26751596,2157,Inconclusive,30582681.0,216.0,22.3872,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
137,1030,2,1,,26751597,2157,Inconclusive,30582681.0,216.0,12.5893,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
138,1195,1,2,,48415552,2157,Active,,,,,DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database,Other,,
139,1332,1,1,,49698843,2157,Active,,,,,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
140,1379,1,2,,11110785,2157,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
141,1452,1,1,,11110784,2157,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
142,1452,1,1,,11110785,2157,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
143,1454,1,1,,11110785,2157,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
144,1457,1,1,,11110785,2157,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
145,1457,1,1,,26751596,2157,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
146,1457,1,1,,26751597,2157,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
147,1458,1,1,,11110785,2157,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
148,1458,1,1,,26751596,2157,Inactive,10937869.0,6607.0,25.1189,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
149,1458,1,1,,26751597,2157,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
150,1460,1,3,,26751596,2157,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
151,1460,1,3,,26751597,2157,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
152,1463,1,1,,26751596,2157,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
153,1463,1,1,,26751597,2157,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
154,1467,1,3,,11110785,2157,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
155,1468,1,1,,26751596,2157,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
156,1468,1,1,,26751597,2157,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
157,1469,1,1,,11110785,2157,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
158,1469,1,1,,26751596,2157,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
159,1469,1,1,,26751597,2157,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
160,1471,2,1,,11110784,2157,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
161,1471,2,1,,11110785,2157,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
162,1471,2,1,,26751596,2157,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
163,1471,2,1,,26751597,2157,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
164,1476,2,1,,11110785,2157,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
165,1477,1,1,,11110785,2157,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
166,1477,1,1,,26751596,2157,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
167,1477,1,1,,26751597,2157,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
168,1478,2,1,,11110785,2157,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
169,1479,1,2,,11110785,2157,Inconclusive,189491771.0,7068.0,5.6234,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
170,1479,1,2,,26751596,2157,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
171,1479,1,2,,26751597,2157,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
172,1487,1,1,,11110785,2157,Inconclusive,27436948.0,4000.0,0.0009,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
173,1487,1,1,,26751596,2157,Inactive,27436948.0,4000.0,,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
174,1490,2,1,,11110785,2157,Inconclusive,10954339.0,,0.7079,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
175,1490,2,1,,26751596,2157,Inconclusive,10954339.0,,25.1189,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
176,1490,2,1,,26751597,2157,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
177,1519,1,3,,11110785,2157,Inconclusive,,,0.0022,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
178,1688,1,1,,26751596,2157,Inconclusive,90903231.0,3064.0,22.3872,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
179,1766,1,1,,11110785,2157,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
180,1766,1,1,,11110785,2157,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
181,1766,1,1,,26751596,2157,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
182,1766,1,1,,26751596,2157,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
183,1768,1,1,,11110785,2157,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
184,1768,1,1,,11110785,2157,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
185,1768,1,1,,26751596,2157,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
186,1768,1,1,,26751596,2157,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
187,1851,1,2,,11110784,2157,Unspecified,,,,,Cytochrome panel assay with activity outcomes,Other,,
188,1851,1,2,,11110785,2157,Unspecified,,,,,Cytochrome panel assay with activity outcomes,Other,,
189,1851,1,2,1.0,11110784,2157,Inactive,4503219.0,1557.0,,,Cytochrome panel assay with activity outcomes,Other,,
190,1851,1,2,1.0,11110785,2157,Inactive,4503219.0,1557.0,,,Cytochrome panel assay with activity outcomes,Other,,
191,1851,1,2,2.0,11110784,2157,Active,68509921.0,1565.0,,,Cytochrome panel assay with activity outcomes,Other,,
192,1851,1,2,2.0,11110785,2157,Inactive,68509921.0,1565.0,,,Cytochrome panel assay with activity outcomes,Other,,
193,1851,1,2,3.0,11110784,2157,Inconclusive,13435386.0,1576.0,,,Cytochrome panel assay with activity outcomes,Other,,
194,1851,1,2,3.0,11110785,2157,Inactive,13435386.0,1576.0,,,Cytochrome panel assay with activity outcomes,Other,,
195,1851,1,2,4.0,11110784,2157,Inconclusive,73915100.0,1544.0,,,Cytochrome panel assay with activity outcomes,Other,,
196,1851,1,2,4.0,11110785,2157,Inconclusive,73915100.0,1544.0,,,Cytochrome panel assay with activity outcomes,Other,,
197,1851,1,2,5.0,11110784,2157,Inconclusive,13699818.0,1559.0,,,Cytochrome panel assay with activity outcomes,Other,,
198,1851,1,2,5.0,11110785,2157,Inconclusive,13699818.0,1559.0,,,Cytochrome panel assay with activity outcomes,Other,,
199,1865,1,1,,11110785,2157,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
200,1865,1,1,,26751596,2157,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
201,1865,1,1,,26751597,2157,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
202,1948,1,1,,11110785,2157,Inactive,,,,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
203,2062,1,2,,85209858,2157,Active,,,,,Ligands of bioamine (Class A) GPCRs,Other,,
204,2101,1,1,,11110785,2157,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
205,2101,1,1,,26751596,2157,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
206,2101,1,1,,26751597,2157,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
207,2107,1,1,,11110785,2157,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
208,2107,1,1,,26751596,2157,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
209,2107,1,1,,26751597,2157,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
210,2112,1,1,,11110785,2157,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
211,2112,1,1,,26751596,2157,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
212,2112,1,1,,26751597,2157,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
213,2147,1,1,,11110785,2157,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
214,2451,1,2,,11110785,2157,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
215,2472,1,2,,11110785,2157,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
216,2517,2,1,,11110785,2157,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
217,2517,2,1,,26751596,2157,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
218,2517,2,1,,26751597,2157,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
219,2528,1,2,,11110785,2157,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
220,2528,1,2,,26751596,2157,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
221,2546,1,1,,11110785,2157,Inactive,188536040.0,19885.0,,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
222,2546,1,1,,26751596,2157,Inconclusive,188536040.0,19885.0,35.4813,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
223,2549,1,1,,11110785,2157,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
224,2549,1,1,,26751596,2157,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
225,2549,1,1,,26751597,2157,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
226,2551,1,1,,11110785,2157,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
227,2551,1,1,,26751596,2157,Inactive,188536040.0,19885.0,,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
228,2660,1,1,,90341282,2157,Inactive,4826730.0,2475.0,,Potency,"Cytometric Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
229,2666,1,1,,90341282,2157,Inactive,4826730.0,2475.0,,Potency,"High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
230,2667,1,1,,90341282,2157,Active,4826730.0,2475.0,13.0918,Potency,High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF Cells,Confirmatory,,
231,2668,1,1,,90341282,2157,Inconclusive,4826730.0,2475.0,26.1216,Potency,Cytometry Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF cells,Confirmatory,,
232,7783,3,4,,103188875,2157,Unspecified,,,,,Unbound fraction (plasma),Other,14971904.0,
233,8002,5,2,,103188875,2157,Unspecified,,,,,Observed volume of distribution,Other,14971904.0,
234,19424,3,4,,103188875,2157,Unspecified,,,,,Partition coefficient (logD7.4),Other,11448232.0,
235,21233,3,3,,103188875,2157,Unspecified,,,,,Partition coefficient of compound in to biological membranes,Other,2002467.0,
236,21234,3,4,,103188875,2157,Unspecified,,,,,Partition coefficient of compound in to octanol/buffer,Other,2002467.0,
237,26362,4,3,,103188875,2157,Unspecified,,,,,Ionization constant (pKa),Other,14971904.0,
238,27167,3,4,,103188875,2157,Unspecified,,,,,Delta logD (logD6.5 - logD7.4),Other,10891117.0,
239,28233,3,3,,103188875,2157,Unspecified,,,,,Fraction ionized (pH 7.4),Other,12061889.0,
240,28235,3,3,,103188875,2157,Unspecified,,,,,Unbound fraction (plasma),Other,12061889.0,
241,28236,3,3,,103188875,2157,Unspecified,,,,,Unbound fraction (tissues),Other,12061889.0,
242,28681,3,4,,103188875,2157,Unspecified,,,,,Partition coefficient (logD6.5),Other,10891117.0,
243,29139,4,3,,103188875,2157,Unspecified,,,,,"Calculated dissociation constant (pKa, calculated with ACD/pKa)",Other,12477351.0,
244,29140,4,3,,103188875,2157,Unspecified,,,,,Apparent value (pKa) calculated with ACD/pKa (experimental pKa value),Other,12477351.0,
245,29337,3,3,,103188875,2157,Unspecified,,,,,Ionisation constant (pKa),Other,12061889.0,
246,29359,3,3,,103188875,2157,Unspecified,,,,,Ionization constant (pKa),Other,10891117.0,
247,29423,3,4,,103188875,2157,Unspecified,,,,,HPLC capacity factor (k'),Other,12061889.0,
248,29813,3,3,,103188875,2157,Unspecified,,,,,Oral bioavailability in human,Other,10891117.0,
249,29925,5,2,,103188875,2157,Unspecified,,,,,Volume of distribution in man (IV dose),Other,12061889.0,
250,45728,7,1,,103188875,2157,Active,,,,,Concentration of compound gave a toxicological response in CHO-K1 cells in MTS assay,Other,11806713.0,
251,45730,8,2,,103188875,2157,Inconclusive,,,,,Agonism of compound towards thyroid response element (TRAF alpha) in CHO-K1 cells; No data,Other,11806713.0,
252,45732,8,2,,103188875,2157,Inconclusive,,,,,Agonism of compound towards thyroid response element (TRAF beta) in CHO-K1 cells; No data,Other,11806713.0,
253,45734,6,2,,103188875,2157,Unspecified,,,10.0,IC50,Antagonism of compound towards thyroid response element (TRAF alpha) in CHO-K1 cells,Confirmatory,11806713.0,
254,45735,6,2,,103188875,2157,Unspecified,,,10.0,IC50,Antagonism of compound towards thyroid response element (TRAF beta) in CHO-K1 cells,Confirmatory,11806713.0,
255,45736,4,4,,103188875,2157,Active,,,2.3,EC50,Reversal of sensitivity of multidrug resistant chinese hamster ovary cell line CHRC/5 expressed as concentration that restores 50% of cytotoxic activity of 5 ug/mL toward doxorubicin,Confirmatory,7608906.0,
256,95584,3,11,,103188875,2157,Unspecified,116412.0,24239.0,,,Percentage inhibition of [3H]nitrendipine binding to L-type [Ca2+] channel dihydropyridine site in rat cortical membranes at 2 uM (70-80 %),Other,11806713.0,
257,95584,3,11,,103188875,2157,Unspecified,6165987.0,29716.0,,,Percentage inhibition of [3H]nitrendipine binding to L-type [Ca2+] channel dihydropyridine site in rat cortical membranes at 2 uM (70-80 %),Other,11806713.0,
258,95584,3,11,,103188875,2157,Unspecified,6165996.0,682930.0,,,Percentage inhibition of [3H]nitrendipine binding to L-type [Ca2+] channel dihydropyridine site in rat cortical membranes at 2 uM (70-80 %),Other,11806713.0,
259,150616,9,2,,103188875,2157,Active,,,3.2,Ki,Concentration giving half of the maximal ATPase activity calculated for the high-affinity binding site of the CHO P-Glycoprotein (P-gp) in two-affinity model,Confirmatory,12477351.0,
260,161281,10,5,,103188875,2157,Active,7531135.0,3757.0,10.0,IC50,Inhibition of human Potassium channel HERG expressed in mammalian cells,Confirmatory,12873512.0,
261,169786,8,1,,103188875,2157,Unspecified,,,,,Effects on liver was determined from serum alanine aminotransferase levels in female (5) rats after 2 weeks of daily oral administration of compound at 100 mg/kg (Control = 23+/-5),Other,11806713.0,
262,169914,8,1,,103188875,2157,Unspecified,,,,,Effects on liver was determined from serum alanine aminotransferase levels in female (5) rats after 2 weeks of daily oral administration of compound at 30 mg/kg (Control = 23+/-5),Other,11806713.0,
263,169915,8,1,,103188875,2157,Unspecified,,,,,Effects on liver was determined from serum alanine aminotransferase levels in female (5) rats after 2 weeks of daily oral administration of compound at 300 mg/kg (Control = 23+/-5),Other,11806713.0,
264,169916,8,1,,103188875,2157,Unspecified,,,,,Effects on liver was determined from serum alanine aminotransferase levels in male (5) rats after 2 weeks of daily oral administration of compound at 100 mg/kg (Control = 30+/-3),Other,11806713.0,
265,169917,8,1,,103188875,2157,Unspecified,,,,,Effects on liver was determined from serum alanine aminotransferase levels in male (5) rats after 2 weeks of daily oral administration of compound at 30 mg/kg (Control = 30+/-3),Other,11806713.0,
266,169918,8,1,,103188875,2157,Unspecified,,,,,Effects on liver was determined from serum alanine aminotransferase levels in male (5) rats after 2 weeks of daily oral administration of compound at 300 mg/kg (Control = 30+/-3),Other,11806713.0,
267,169946,8,1,,103188875,2157,Unspecified,,,,,Effects on liver was determined from serum aspartate aminotransferase levels in female (5) rats after 2 weeks of daily oral administration of compound at 100 mg/kg (Control = 106+/-18),Other,11806713.0,
268,169947,8,1,,103188875,2157,Unspecified,,,,,Effects on liver was determined from serum aspartate aminotransferase levels in female (5) rats after 2 weeks of daily oral administration of compound at 30 mg/kg (Control = 106+/-18),Other,11806713.0,
269,169948,8,1,,103188875,2157,Unspecified,,,,,Effects on liver was determined from serum aspartate aminotransferase levels in female (5) rats after 2 weeks of daily oral administration of compound at 300 mg/kg (Control = 106+/-18),Other,11806713.0,
270,169949,8,1,,103188875,2157,Unspecified,,,,,Effects on liver was determined from serum aspartate aminotransferase levels in male (5) rats after 2 weeks of daily oral administration of compound at 100 mg/kg (Control = 111+/-21),Other,11806713.0,
271,169950,8,1,,103188875,2157,Unspecified,,,,,Effects on liver was determined from serum aspartate aminotransferase levels in male (5) rats after 2 weeks of daily oral administration of compound at 30 mg/kg (Control = 111+/-21),Other,11806713.0,
272,170074,8,1,,103188875,2157,Unspecified,,,,,Effects on liver was determined from serum aspartate aminotransferase levels in male (5) rats after 2 weeks of daily oral administration of compound at 300 mg/kg (Control = 111+/-21),Other,11806713.0,
273,173084,6,1,,103188875,2157,Unspecified,,,,,Effects on liver was determined from serum cholesterol levels in female (5) rats after 2 weeks of daily oral administration of compound at 100 mg/kg (Control = 0.73+/-0.05),Other,11806713.0,
274,173085,6,1,,103188875,2157,Unspecified,,,,,Effects on liver was determined from serum cholesterol levels in female (5) rats after 2 weeks of daily oral administration of compound at 30 mg/kg (Control = 0.73+/-0.05),Other,11806713.0,
275,173086,6,1,,103188875,2157,Unspecified,,,,,Effects on liver was determined from serum cholesterol levels in female (5) rats after 2 weeks of daily oral administration of compound at 300 mg/kg (Control = 0.73+/-0.05),Other,11806713.0,
276,173087,6,1,,103188875,2157,Unspecified,,,,,Effects on liver was determined from serum cholesterol levels in male (5) rats after 2 weeks of daily oral administration of compound at 100 mg/kg (Control = 0.67+/-0.13),Other,11806713.0,
277,173088,6,1,,103188875,2157,Unspecified,,,,,Effects on liver was determined from serum cholesterol levels in male (5) rats after 2 weeks of daily oral administration of compound at 30 mg/kg (Control = 0.67+/-0.13),Other,11806713.0,
278,173089,6,1,,103188875,2157,Unspecified,,,,,Effects on liver was determined from serum cholesterol levels in male (5) rats after 2 weeks of daily oral administration of compound at 300 mg/kg (Control = 0.67+/-0.13),Other,11806713.0,
279,190481,5,3,,103188875,2157,Unspecified,,,,,Serum concentrations of T3 in rats after 2 weeks of daily oral administration of compound at 100 mg/kg (Control = 0.74+/-0.15),Other,11806713.0,
280,190482,5,3,,103188875,2157,Unspecified,,,,,Serum concentrations of T3 in rats after 2 weeks of daily oral administration of compound at 30 mg/kg (Control = 0.74+/-0.15),Other,11806713.0,
281,190483,5,3,,103188875,2157,Unspecified,,,,,Serum concentrations of T3 in rats after 2 weeks of daily oral administration of compound at 300 mg/kg (Control = 0.74+/-0.15),Other,11806713.0,
282,190484,5,3,,103188875,2157,Unspecified,,,,,Serum concentrations of T4 in rats after 2 weeks of daily oral administration of compound at 100 mg/kg (Control = 33.1+/-5.00),Other,11806713.0,
283,190485,5,3,,103188875,2157,Unspecified,,,,,Serum concentrations of T4 in rats after 2 weeks of daily oral administration of compound at 30 mg/kg (Control = 33.1+/-5.00),Other,11806713.0,
284,190486,5,3,,103188875,2157,Unspecified,,,,,Serum concentrations of T4 in rats after 2 weeks of daily oral administration of compound at 300 mg/kg (Control = 33.1+/-5.00),Other,11806713.0,
285,190487,3,3,,103188875,2157,Unspecified,,,,,Serum concentrations of Thyrotropin in rats after 2 weeks of daily oral administration of compound at 100 mg/kg (Control = 11.00+/-1.97),Other,11806713.0,
286,190488,3,3,,103188875,2157,Unspecified,,,,,Serum concentrations of Thyrotropin in rats after 2 weeks of daily oral administration of compound at 30 mg/kg (Control = 11.00+/-1.97),Other,11806713.0,
287,190489,3,3,,103188875,2157,Unspecified,,,,,Serum concentrations of Thyrotropin in rats after 2 weeks of daily oral administration of compound at 300 mg/kg (Control = 11.00+/-1.97),Other,11806713.0,
288,213170,9,1,,103188875,2157,Active,,,0.65,IC50,Concentration required to inhibit 50% of binding of [125I]-T3 to human Thyroid hormone receptor alpha-1 in CHO-K1 cells,Confirmatory,11806713.0,
289,213181,9,1,,103188875,2157,Active,,,0.6,IC50,Concentration required to inhibit 50% of binding of [125I]T3 to human Thyroid hormone receptor beta 1 in CHO-K1 cells,Confirmatory,11806713.0,
290,226029,3,4,,103188875,2157,Unspecified,,,,,"Tested for the multidrug resistance reversal activity against P388 murine leukemia cell line, activity is expressed as RF(ED50 with no adriamycin (ADR)/ED50 with 200 nM ADR)",Other,11087578.0,
291,226357,3,10,,103188875,2157,Unspecified,116447.0,81574.0,,,Percentage inhibition of [3H]batrachotoxin binding to aconitine site of rat forebrain membrane sodium channel at 2 uM (60-70%),Other,11806713.0,
292,226357,3,10,,103188875,2157,Unspecified,116448.0,24766.0,,,Percentage inhibition of [3H]batrachotoxin binding to aconitine site of rat forebrain membrane sodium channel at 2 uM (60-70%),Other,11806713.0,
293,226357,3,10,,103188875,2157,Unspecified,116449.0,497770.0,,,Percentage inhibition of [3H]batrachotoxin binding to aconitine site of rat forebrain membrane sodium channel at 2 uM (60-70%),Other,11806713.0,
294,239296,7,2,,103188875,2157,Active,,,0.062,Ki,Affinity for ERG2 of Saccharomyces cerevisiae using [3H]ifenprodil or (+)-[3H]pentazocine radioligand,Confirmatory,16033255.0,
295,239347,7,2,,103188875,2157,Active,,,0.001,Ki,Affinity for sigma receptor type 1 of guinea pig using [3H]ifenprodil or (+)-[3H]pentazocine radioligand,Confirmatory,16033255.0,
296,239597,8,5,,103188875,2157,Active,17374795.0,10682.0,0.025,Ki,Affinity for human EMP expressed in ERG2 deficient strain of Saccharomyces cerevisiae using [3H]ifenprodil or (+)-[3H]pentazocine as radioligand,Confirmatory,16033255.0,
297,243151,7,2,,103188875,2157,Active,,,10.0,IC50,Inhibitory concentration against potassium channel HERG,Confirmatory,15911273.0,
298,243422,3,10,,103188875,2157,Unspecified,116241312.0,1576.0,,,log (1/Km) value for human liver microsome cytochrome P450 3A4,Other,15990295.0,
299,250135,3,4,,103188875,2157,Unspecified,,,,,Inhibition of compound against MES-SA/DX5 cell line was determined using P-glycoprotein assay,Other,15828831.0,
300,259824,9,1,,103188875,2157,Active,,,,IC50,Antiprotozoal activity against Trypanosoma cruzi epimastigotes,Confirmatory,16451055.0,
301,259825,9,1,,103188875,2157,Active,,,,IC50,Antiprotozoal activity against Trypanosoma cruzi amastigotes,Confirmatory,16451055.0,
302,259826,11,2,,103188875,2157,Active,,,8.0,IC50,Inhibitory activity against Trypanosoma cruzi glycosomal squalene synthase,Confirmatory,16451055.0,
303,259827,11,2,,103188875,2157,Active,,,12.0,IC50,Inhibitory activity against Trypanosoma cruzi microsomal squalene synthase,Confirmatory,16451055.0,
304,259828,4,8,,103188875,2157,Inactive,74844344.0,,,,Inhibitory activity against recombinant farnesyl diphosphate synthase at 50 uM,Other,16451055.0,
305,259829,3,8,,103188875,2157,Active,,,,,Inhibitory activity against oxidosqualene cyclase,Other,16451055.0,
306,259830,3,3,,103188875,2157,Active,,,,,Disruption of calcium homeostasis in Trypanosoma cruzi,Other,16451055.0,
307,259831,3,3,,103188875,2157,Active,,,,,Ability to block ergosterol biosynthesis in Trypanosoma cruzi,Other,16451055.0,
308,275597,4,5,,103188875,2157,Unspecified,,,,,Activity against alternating current-induced arrhythmia in guinea pig left atrium at 100 uM,Other,17228875.0,
309,275602,3,5,,103188875,2157,Unspecified,,,,,Negative inotropic activity assessed as decrease in developed tension in isolated guinea pig left atrium at 100 uM relative to control,Other,17228875.0,
310,275609,3,5,,103188875,2157,Unspecified,,,,,Negative chronotropic activity assessed as decrease in atrial rate in isolated guinea pig right atrium at 100 uM relative to control,Other,17228875.0,
311,275614,3,4,,103188875,2157,Unspecified,,,,,Inhibition of calcium-induced contraction of potassium ion depolarized guinea pig aortic strips at 100 uM,Other,17228875.0,
312,275616,3,4,,103188875,2157,Unspecified,,,,,Heart rate in spontaneously beating Langendorff-perfused guinea pig heart at 1 nM,Other,17228875.0,
313,275617,3,4,,103188875,2157,Unspecified,,,,,Atrioventricular conduction time in spontaneously beating Langendorff-perfused guinea pig heart at 1 nM,Other,17228875.0,
314,275618,3,4,,103188875,2157,Unspecified,,,,,Intraventricular conduction time in spontaneously beating Langendorff-perfused guinea pig heart at 1 nM,Other,17228875.0,
315,275619,3,4,,103188875,2157,Unspecified,,,,,Ventricular action potential duration in spontaneously beating Langendorff-perfused guinea pig heart at 1 nM,Other,17228875.0,
316,275620,3,4,,103188875,2157,Unspecified,,,,,Heart rate in spontaneously beating Langendorff-perfused guinea pig heart at 10 nM,Other,17228875.0,
317,275621,3,4,,103188875,2157,Unspecified,,,,,Atrioventricular conduction time in spontaneously beating Langendorff-perfused guinea pig heart at 10 nM,Other,17228875.0,
318,275622,3,4,,103188875,2157,Unspecified,,,,,Intraventricular conduction time in spontaneously beating Langendorff-perfused guinea pig heart at 10 nM,Other,17228875.0,
319,275623,3,4,,103188875,2157,Unspecified,,,,,Ventricular action potential duration in spontaneously beating Langendorff-perfused guinea pig heart at 10 nM,Other,17228875.0,
320,275624,3,4,,103188875,2157,Unspecified,,,,,Heart rate in spontaneously beating Langendorff-perfused guinea pig heart at 0.1uM,Other,17228875.0,
321,275625,3,4,,103188875,2157,Unspecified,,,,,Atrioventricular conduction time in spontaneously beating Langendorff-perfused guinea pig heart at 0.1 uM,Other,17228875.0,
322,275626,3,4,,103188875,2157,Unspecified,,,,,Intraventricular conduction time in spontaneously beating Langendorff-perfused guinea pig heart at 0.1 uM,Other,17228875.0,
323,275627,3,4,,103188875,2157,Unspecified,,,,,Ventricular action potential duration in spontaneously beating Langendorff-perfused guinea pig heart at 0.1 uM,Other,17228875.0,
324,275628,3,4,,103188875,2157,Unspecified,,,,,Heart rate in spontaneously beating Langendorff-perfused guinea pig heart at 1 uM,Other,17228875.0,
325,275629,3,4,,103188875,2157,Unspecified,,,,,Atrioventricular conduction time in spontaneously beating Langendorff-perfused guinea pig heart at 1 uM,Other,17228875.0,
326,275630,3,4,,103188875,2157,Unspecified,,,,,Intraventricular conduction time in spontaneously beating Langendorff-perfused guinea pig heart at 1 uM,Other,17228875.0,
327,275631,3,4,,103188875,2157,Unspecified,,,,,Ventricular action potential duration in spontaneously beating Langendorff-perfused guinea pig heart at 1 uM,Other,17228875.0,
328,275632,3,4,,103188875,2157,Unspecified,,,,,Heart rate in spontaneously beating Langendorff-perfused guinea pig heart at 10 uM,Other,17228875.0,
329,275633,3,4,,103188875,2157,Unspecified,,,,,Atrioventricular conduction time in spontaneously beating Langendorff-perfused guinea pig heart at 10 uM,Other,17228875.0,
330,275634,3,4,,103188875,2157,Unspecified,,,,,Intraventricular conduction time in spontaneously beating Langendorff-perfused guinea pig heart at 10 uM,Other,17228875.0,
331,275635,3,4,,103188875,2157,Unspecified,,,,,Ventricular action potential duration in spontaneously beating Langendorff-perfused guinea pig heart at 10 uM,Other,17228875.0,
332,275640,6,4,,103188875,2157,Active,,,5.57,EC50,Negative chronotropic activity assessed as decrease in atrial rate in isolated guinea pig right atrium,Confirmatory,17228875.0,
333,288774,8,1,,103188875,2157,Unspecified,,,,,Hemodynamic effect in intravenously dosed Sprague-Dawley rat with ischemia-induced arrhythmia assessed as dose producing 10% reduction in systemic blood pressure,Other,17506538.0,
334,294418,6,2,,103188875,2157,Active,,,,,Solubility in phosphate buffer at pH 5.0,Other,17316909.0,
335,294419,6,2,,103188875,2157,Active,,,,,Solubility in phosphate buffer at pH 7.4,Other,17316909.0,
336,294420,3,6,,103188875,2157,Unspecified,,,,,Lipophilicity in phosphate buffer at pH 7.5,Other,17316909.0,
337,294421,3,4,,103188875,2157,Unspecified,,,,,Affinity to immobilized artificial membrane by reversed phase HPLC,Other,17316909.0,
338,311524,4,3,,103188875,2157,Unspecified,,,,,Oral bioavailability in human,Other,17870541.0,
339,311934,3,3,,103188875,2157,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,18027916.0,
340,311935,3,4,,103188875,2157,Unspecified,,,,,"Partition coefficient, log P of the compound",Other,18027916.0,
341,324368,3,4,,103188875,2157,Unspecified,,,,,Induction of light chain 3-GFP level in human H4 cells at 3.7 uM after 24 hrs by high throughput fluorescence microscopy relative to control,Other,18024584.0,
342,324420,3,4,,103188875,2157,Unspecified,,,,,Increase in light chain 3-GFP+ autophagosome vesicle number per cell in human H4 cells at 3.7 uM after 24 hrs by high throughput fluorescence microscopy relative to control,Other,18024584.0,
343,324472,3,4,,103188875,2157,Unspecified,,,,,Increase in light chain 3-GFP+ autophagosome vesicle area per cell in human H4 cells at 3.7 uM after 24 hrs by high throughput fluorescence microscopy relative to control,Other,18024584.0,
344,324524,3,4,,103188875,2157,Unspecified,,,,,Increase in light chain 3-GFP+ autophagosome vesicle intensity per cell in human H4 cells at 3.7 uM after 24 hrs by high throughput fluorescence microscopy relative to control,Other,18024584.0,
345,324576,3,4,,103188875,2157,Unspecified,,,,,Effect on FYVE-RFP+ vesicle intensity per cell in human H4 cells after 2 hrs relative to control,Other,18024584.0,
346,324577,3,4,,103188875,2157,Unspecified,,,,,Effect on FYVE-RFP+ vesicle intensity per cell in human H4 cells after 4 hrs relative to control,Other,18024584.0,
347,324578,3,4,,103188875,2157,Unspecified,,,,,Effect on FYVE-RFP+ vesicle intensity per cell in human H4 cells after 8 hrs relative to control,Other,18024584.0,
348,324582,3,4,,103188875,2157,Unspecified,,,,,Increase in long-lived protein degradation in human H4 cells after 1 hr relative to control,Other,18024584.0,
349,324583,3,4,,103188875,2157,Unspecified,,,,,Increase in long-lived protein degradation in human H4 cells after 2 hrs relative to control,Other,18024584.0,
350,324584,3,4,,103188875,2157,Unspecified,,,,,Increase in long-lived protein degradation in human H4 cells after 4 hrs relative to control,Other,18024584.0,
351,324585,3,4,,103188875,2157,Unspecified,,,,,Increase in long-lived protein degradation in human H4 cells after 24 hrs relative to control,Other,18024584.0,
352,324587,3,4,,103188875,2157,Active,,,,,Increase in ratio of light chain 3 subunit 2 to light chain 3 subunit 1 in human H4 cells at 3.7 uM after 4 hrs by Western blot,Other,18024584.0,
353,324595,3,4,,103188875,2157,Unspecified,,,,,Reduction of poly(Q) level in human H4 cells expressing EGFP-Q79-HA after 24 hrs,Other,18024584.0,
354,324597,3,10,,103188875,2157,Inactive,1169735.0,2475.0,,,Effect on mTOR phosphorylation in human H4 cells at 3.7 uM after 4 hrs,Other,18024584.0,
355,397237,3,4,,103188875,2157,Active,,,,,Antiarrhythmic activity in langendorff ischemia-reperfused Sprague-Dawley rat heart assessed as cardiac protection at 1 uM,Other,19185489.0,
356,397240,3,4,,103188875,2157,Unspecified,,,,,Cardioprotective effect in isolated langendorff ischemia-reperfused Sprague-Dawley rat heart assessed as reduction of heart rate at 1 uM after 20 mins by RR interval ECG signal,Other,19185489.0,
357,397390,3,4,,103188875,2157,Unspecified,,,,,Cardioprotective effect in isolated langendorff ischemia-reperfused Sprague-Dawley rat heart assessed as duration of QT intervals at 1 uM after 20 mins,Other,19185489.0,
358,397391,5,1,,103188875,2157,Unspecified,,,,,Cardioprotective effect in isolated langendorff ischemia-reperfused Sprague-Dawley rat heart assessed as duration of QTc intervals at 1 uM after 20 mins,Other,19185489.0,
359,404304,3,10,,103188875,2157,Unspecified,308153583.0,1244.0,,,Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control,Other,18457386.0,
360,406410,3,4,,103188875,2157,Active,,,,,Protection against Bacillus anthracis protective antigen and lethal toxin-diphtheria toxin chimeric protein mediated cytotoxicity in mouse RAW264.7 cells assessed as cell viability,Other,17485504.0,
361,406411,3,10,,103188875,2157,Unspecified,50402185.0,,,,Protection against Bacillus anthracis lethal toxin-mediated cytotoxicity in mouse RAW264.7 cells assessed as change in viability at 0.125 to 12.5 uM relative to toxin-treated control,Other,17485504.0,
362,406412,9,5,,103188875,2157,Active,50402185.0,,3.5,IC50,Protection against Bacillus anthracis lethal toxin-mediated cytotoxicity in mouse RAW264.7 cells assessed as change in viability after 24 hrs by WST1 dye reduction assay,Confirmatory,17485504.0,
363,406413,3,4,,103188875,2157,Unspecified,,,,,Protection against Bacillus anthracis protective antigen and lethal toxin-diphtheria toxin chimeric protein mediated cytotoxicity in mouse RAW264.7 cells assessed as cell viability after 24 hrs by WST1 dye reduction assay,Other,17485504.0,
364,406414,3,9,,103188875,2157,Active,75360764.0,,,,Protection against diphtheria toxin-mediated cytotoxicity in CHOK1 cells assessed as cell viability after 48 hrs by WST1 dye reduction assay,Other,17485504.0,
365,406415,3,3,,103188875,2157,Active,,,,,Protection against Bacillus anthracis protective antigen and lethal toxin-diphtheria toxin chimeric protein-mediated cytotoxicity in CHOK1 cells assessed as cell viability after 48 hrs by WST1 dye reduction assay,Other,17485504.0,
366,406416,3,10,,103188875,2157,Active,729244.0,3361726.0,,,Inhibition of Bacillus anthracis edema toxin-mediated intoxication in CHOK1 cells assessed as cAMP levels after 4 hrs by HTRF assay,Other,17485504.0,
367,406417,3,3,,103188875,2157,Inactive,,,,,Inhibition of cholera toxin-mediated intoxication in CHOK1 cells assessed as cAMP levels after 4 hrs by HTRF assay,Other,17485504.0,
368,406418,3,10,,103188875,2157,Active,50402185.0,,,,Inhibition of Bacillus anthracis lethal toxin entry in mouse RAW264.7 cells assessed as MEK cleavage at 12.5 uM after 4 hrs,Other,17485504.0,
369,406419,3,10,,103188875,2157,Inactive,17380160.0,3361714.0,,,Inhibition of Bacillus anthracis protective antigen binding to cell surface of mouse RAW264.7 cells at 12.5 uM after 2 hrs by flow cytometry,Other,17485504.0,
370,406420,3,10,,103188875,2157,Active,17380160.0,3361714.0,,,Inhibition of Bacillus anthracis protective antigen pore formation in mouse RAW264.7 cells at 12.5 uM after 2 hrs,Other,17485504.0,
371,406421,3,3,,103188875,2157,Unspecified,,,,,Protection against Bacillus anthracis lethal toxin-mediated intoxication in Fischer 344 rat assessed as time to death at 5.4 mg/kg administered through cannula,Other,17485504.0,
372,406422,3,3,,103188875,2157,Unspecified,,,,,Protection against Bacillus anthracis lethal toxin-mediated intoxication in Fischer 344 rat assessed as time to death at 54 mg/kg administered through cannula,Other,17485504.0,
373,406423,3,3,,103188875,2157,Unspecified,,,,,Toxicity in Bacillus anthracis lethal toxin-mediated intoxicated Fischer 344 rat assessed as adverse side effects administered through cannula,Other,17485504.0,
374,406424,7,1,,103188875,2157,Active,,,,,Drug level in human serum,Other,17485504.0,
375,406425,6,2,,103188875,2157,Active,,,2.5,IC50,Antimalarial activity against Plasmodium falciparum,Confirmatory,17485504.0,
376,408340,8,5,,103188875,2157,Active,7531135.0,3757.0,10.0,IC50,Inhibition of human ERG expressed in CHO cells by whole cell patch clamp technique,Confirmatory,18448342.0,
377,425652,7,2,,103188875,2157,Unspecified,,,,,Total body clearance in human,Other,19445515.0,
378,425653,7,2,,103188875,2157,Unspecified,,,,,Renal clearance in human,Other,19445515.0,
379,444050,7,1,,103188875,2157,Unspecified,,,,,Fraction unbound in human plasma,Other,20070106.0,
380,444051,6,2,,103188875,2157,Unspecified,,,,,Total clearance in human,Other,20070106.0,
381,444052,6,2,,103188875,2157,Unspecified,,,,,Hepatic clearance in human,Other,20070106.0,
382,444053,6,2,,103188875,2157,Unspecified,,,,,Renal clearance in human,Other,20070106.0,
383,444054,6,1,,103188875,2157,Unspecified,,,,,Oral bioavailability in human,Other,20070106.0,
384,444055,3,3,,103188875,2157,Unspecified,,,,,Fraction absorbed in human,Other,20070106.0,
385,444056,3,3,,103188875,2157,Unspecified,,,,,Fraction escaping gut-wall elimination in human,Other,20070106.0,
386,444057,3,3,,103188875,2157,Unspecified,,,,,Fraction escaping hepatic elimination in human,Other,20070106.0,
387,444058,6,2,,103188875,2157,Unspecified,,,,,Volume of distribution at steady state in human,Other,20070106.0,
388,445740,3,11,,103188875,2157,Inactive,38258636.0,134864.0,,,Activation of human TAAR1 expressed in CHOK1 cells assessed as cAMP accumulation at 0.1 to 1 uM,Other,19740654.0,
389,445742,3,4,,103188875,2157,Inactive,,,,,Effect on calcium mobilization in CHO cells stably expressing Galpha16,Other,19740654.0,
390,463106,1,2,,90341282,2157,Inactive,188528692.0,9099.0,,Potency,qHTS Validation Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
391,485281,1,1,,11110785,2157,Inactive,254220970.0,,,Potency,qHTS Assay for Identification of Novel General Anesthetics,Confirmatory,,
392,485290,1,1,,11110785,2157,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
393,485290,1,1,,26751596,2157,Inactive,20150581.0,,56.2341,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
394,485290,1,1,,26751597,2157,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
395,485295,1,2,,90341282,2157,Inactive,30027657.0,,,Potency,qHTS Validation Assay for the Inhibitors of DNA Replication in Gram-Positive Bacteria,Confirmatory,,
396,485297,1,1,,90341282,2157,Inactive,4759012.0,9367.0,,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
397,485298,1,1,,90341282,2157,Inactive,,,4.6109,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
398,485313,1,2,,90341282,2157,Inactive,255652944.0,4864.0,,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
399,485342,1,2,,90341282,2157,Inactive,5454140.0,7251.0,,Potency,qHTS Validation Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
400,485345,1,2,,90341282,2157,Inactive,,,,Potency,qHTS Validation Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
401,485350,1,2,,99300902,2157,Inactive,126642418.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme BasE,Screening,,
402,485366,1,2,,90341282,2157,Inactive,4501969.0,154.0,,Potency,qHTS validation assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
403,485368,1,2,,90341282,2157,Inconclusive,72386991.0,3656265.0,37.933,Potency,qHTS Validation Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
404,488772,1,1,,90341282,2157,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
405,488773,1,2,,90341282,2157,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
406,488816,1,1,,90341282,2157,Inactive,4758356.0,2237.0,,Potency,qHTS Validation Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1),Confirmatory,,
407,488837,1,1,,90341282,2157,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
408,488949,1,2,,90341282,2157,Inactive,41055989.0,54737.0,,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
409,488953,1,1,,90341282,2157,Active,187960037.0,10951.0,44.6684,Potency,qHTS Validation Assay for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
410,488978,1,1,,90341282,2157,Inactive,45359078.0,,,Potency,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity: MmCpn Primary Screen,Confirmatory,,
411,488981,1,1,,90341282,2157,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Agonists,Confirmatory,,
412,488982,1,1,,90341282,2157,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Potentiators,Confirmatory,,
413,488983,1,1,,90341282,2157,Inconclusive,4503383.0,1812.0,11.2202,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Antagonists,Confirmatory,,
414,491137,3,4,,103188875,2157,Unspecified,,,,,Vasorelaxant activity in potassium depolarized guinea pig aortic strip assessed as inhibition of calcium-induced contraction at 100 uM,Other,20509610.0,
415,491140,5,3,,103188875,2157,Active,,,5.57,EC50,Negative chronotropic activity against potassium-induced contraction in guinea pig left atrium assessed as decrease atrial rate,Confirmatory,20509610.0,
416,491144,3,4,,103188875,2157,Unspecified,,,,,Negative chronotropic activity against potassium-induced contraction in guinea pig left atrium assessed as decrease atrial rate at 100 uM relative to control,Other,20509610.0,
417,491150,3,4,,103188875,2157,Unspecified,,,,,Negative inotropic activity against potassium-induced contraction in guinea pig left atrium assessed as decrease in developed tension at 100 uM relative to control,Other,20509610.0,
418,491157,3,4,,103188875,2157,Unspecified,,,,,Antiarrhythmic activity in sinusoidal alternating current-induced guinea pig left atrium assessed as increase in current strength at which extra beats occur at 100 uM measured every 30 mins,Other,20509610.0,
419,491159,3,4,,103188875,2157,Unspecified,,,,,Cardioprotective effect in Langendorff perfused guinea pig spontaneously beating left atria assessed as duration of ventricular action potential at 10 uM (RVb = 140 to 161 +/- 2 to 8 ms),Other,20509610.0,
420,491160,3,4,,103188875,2157,Unspecified,,,,,Cardioprotective effect in Langendorff perfused guinea pig spontaneously beating left atria assessed as duration of ventricular action potential at 1 uM (RVb = 140 to 161 +/- 2 to 8 ms),Other,20509610.0,
421,491161,3,4,,103188875,2157,Unspecified,,,,,Cardioprotective effect in Langendorff perfused guinea pig spontaneously beating left atria assessed as atrioventicular conduction time at 1 uM (RVb = 50 to 55 +/- 1 to 4 ms),Other,20509610.0,
422,492881,3,4,,103188875,2157,Unspecified,,,,,Cardioprotective effect in Langendorff perfused guinea pig spontaneously beating left atria assessed as duration of ventricular action potential at 0.1 uM (RVb = 140 to 161 +/- 2 to 8 ms),Other,20509610.0,
423,492882,3,4,,103188875,2157,Unspecified,,,,,Cardioprotective effect in Langendorff perfused guinea pig spontaneously beating left atria assessed as duration of ventricular action potential at 0.01 uM (RVb = 140 to 161 +/- 2 to 8 ms),Other,20509610.0,
424,492883,3,4,,103188875,2157,Unspecified,,,,,Cardioprotective effect in Langendorff perfused guinea pig spontaneously beating left atria assessed as duration of ventricular action potential at 0.001 uM (RVb = 140 to 161 +/- 2 to 8 ms),Other,20509610.0,
425,492884,3,4,,103188875,2157,Unspecified,,,,,Cardioprotective effect in Langendorff perfused guinea pig spontaneously beating left atria assessed as intraventicular conduction time at 10 uM (RVb = 19 to 24 +/- 1 to 2 ms),Other,20509610.0,
426,492885,3,4,,103188875,2157,Unspecified,,,,,Cardioprotective effect in Langendorff perfused guinea pig spontaneously beating left atria assessed as intraventicular conduction time at 1 uM (RVb = 19 to 24 +/- 1 to 2 ms),Other,20509610.0,
427,492886,3,4,,103188875,2157,Unspecified,,,,,Cardioprotective effect in Langendorff perfused guinea pig spontaneously beating left atria assessed as intraventicular conduction time at 0.1 uM (RVb = 19 to 24 +/- 1 to 2 ms),Other,20509610.0,
428,492887,3,4,,103188875,2157,Unspecified,,,,,Cardioprotective effect in Langendorff perfused guinea pig spontaneously beating left atria assessed as intraventicular conduction time at 0.01 uM (RVb = 19 to 24 +/- 1 to 2 ms),Other,20509610.0,
429,492888,3,4,,103188875,2157,Unspecified,,,,,Cardioprotective effect in Langendorff perfused guinea pig spontaneously beating left atria assessed as intraventicular conduction time at 0.001 uM (RVb = 19 to 24 +/- 1 to 2 ms),Other,20509610.0,
430,492889,3,4,,103188875,2157,Unspecified,,,,,Cardioprotective effect in Langendorff perfused guinea pig spontaneously beating left atria assessed as atrioventicular conduction time at 10 uM (RVb = 50 to 55 +/- 1 to 4 ms),Other,20509610.0,
431,492890,3,4,,103188875,2157,Unspecified,,,,,Cardioprotective effect in Langendorff perfused guinea pig spontaneously beating left atria assessed as atrioventicular conduction time at 0.1 uM (RVb = 50 to 55 +/- 1 to 4 ms),Other,20509610.0,
432,492891,3,4,,103188875,2157,Unspecified,,,,,Cardioprotective effect in Langendorff perfused guinea pig spontaneously beating left atria assessed as atrioventicular conduction time at 0.01 uM (RVb = 50 to 55 +/- 1 to 4 ms),Other,20509610.0,
433,492892,3,4,,103188875,2157,Unspecified,,,,,Cardioprotective effect in Langendorff perfused guinea pig spontaneously beating left atria assessed as atrioventicular conduction time at 0.001 uM (RVb = 50 to 55 +/- 1 to 4 ms),Other,20509610.0,
434,492893,3,5,,103188875,2157,Unspecified,,,,,Cardioprotective effect in Langendorff perfused guinea pig spontaneously beating left atria assessed as heart rat at 0.001 uM (RVb = 175 to 190 +/- 5 to 11 bpm),Other,20509610.0,
435,492894,3,5,,103188875,2157,Unspecified,,,,,Cardioprotective effect in Langendorff perfused guinea pig spontaneously beating left atria assessed as heart rat at 0.01 uM (RVb = 175 to 190 +/- 5 to 11 bpm),Other,20509610.0,
436,492895,3,5,,103188875,2157,Unspecified,,,,,Cardioprotective effect in Langendorff perfused guinea pig spontaneously beating left atria assessed as heart rat at 0.1 uM (RVb = 175 to 190 +/- 5 to 11 bpm),Other,20509610.0,
437,492896,3,5,,103188875,2157,Unspecified,,,,,Cardioprotective effect in Langendorff perfused guinea pig spontaneously beating left atria assessed as heart rat at 1 uM (RVb = 175 to 190 +/- 5 to 11 bpm),Other,20509610.0,
438,492897,3,5,,103188875,2157,Unspecified,,,,,Cardioprotective effect in Langendorff perfused guinea pig spontaneously beating left atria assessed as heart rat at 10 uM (RVb = 175 to 190 +/- 5 to 11 bpm),Other,20509610.0,
439,493033,1,2,,99300902,2157,Inactive,614089026.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme MbtI,Other,,
440,493106,1,1,,90341282,2157,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
441,493107,1,1,,90341282,2157,Inconclusive,116283940.0,79915.0,16.3535,Potency,Validation screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
442,493153,1,1,,90341282,2157,Inactive,,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
443,493153,1,1,,90341282,2157,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
444,493164,1,2,,90341282,2157,Inconclusive,6679377.0,18792.0,14.6892,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
445,493164,1,2,,90341282,2157,Inconclusive,7242179.0,18793.0,14.6892,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
446,493164,1,2,,90341282,2157,Inconclusive,257471003.0,18815.0,14.6892,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
447,496817,4,2,,103188875,2157,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma cruzi,Confirmatory,20185316.0,
448,496818,4,2,,103188875,2157,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei brucei,Confirmatory,20185316.0,
449,496819,4,2,,103188875,2157,Inconclusive,,,,IC50,Antimicrobial activity against Plasmodium falciparum,Confirmatory,20185316.0,
450,496820,4,2,,103188875,2157,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei,Confirmatory,20185316.0,
451,496821,4,2,,103188875,2157,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania,Confirmatory,20185316.0,
452,496823,4,2,,103188875,2157,Inconclusive,,,,IC50,Antimicrobial activity against Trichomonas vaginalis,Confirmatory,20185316.0,
453,496824,4,2,,103188875,2157,Inconclusive,,,,IC50,Antimicrobial activity against Toxoplasma gondii,Confirmatory,20185316.0,
454,496825,4,2,,103188875,2157,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania mexicana,Confirmatory,20185316.0,
455,496826,4,2,,103188875,2157,Inconclusive,,,,IC50,Antimicrobial activity against Entamoeba histolytica,Confirmatory,20185316.0,
456,496827,4,2,,103188875,2157,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania amazonensis,Confirmatory,20185316.0,
457,496828,4,2,,103188875,2157,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania donovani,Confirmatory,20185316.0,
458,496829,4,2,,103188875,2157,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania infantum,Confirmatory,20185316.0,
459,496830,4,2,,103188875,2157,Inconclusive,,,,IC50,Antimicrobial activity against Leishmania major,Confirmatory,20185316.0,
460,496831,4,2,,103188875,2157,Inconclusive,,,,IC50,Antimicrobial activity against Cryptosporidium parvum,Confirmatory,20185316.0,
461,496832,4,2,,103188875,2157,Inconclusive,,,,IC50,Antimicrobial activity against Trypanosoma brucei rhodesiense,Confirmatory,20185316.0,
462,497005,4,2,,103188875,2157,Inconclusive,,,,IC50,Antimicrobial activity against Pneumocystis carinii,Confirmatory,20185316.0,
463,504327,1,1,,11110785,2157,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
464,504327,1,1,,90341282,2157,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
465,504332,1,1,,11110785,2157,Inconclusive,168985070.0,,6.3096,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
466,504332,1,1,,90341282,2157,Inactive,168985070.0,,1.1917,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
467,504536,1,1,,90341282,2157,Inconclusive,5453898.0,5300.0,4.7755,Potency,qHTS Validation Assay to Find Inhibitors of Pin1,Confirmatory,,
468,504547,1,1,,90341282,2157,Inactive,115503961.0,4357161.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
469,504548,1,2,,90341282,2157,Inactive,157877932.0,5655980.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Mutase,Confirmatory,,
470,504749,1,3,,26751596,2157,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
471,504749,1,3,,104171110,2157,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
472,504749,1,3,1.0,26751596,2157,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
473,504749,1,3,2.0,104171110,2157,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
474,504749,1,3,3.0,104171110,2157,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
475,504749,1,3,4.0,26751596,2157,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
476,504749,1,3,5.0,104171110,2157,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
477,504749,1,3,6.0,26751596,2157,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
478,504749,1,3,7.0,26751596,2157,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
479,504749,1,3,8.0,26751596,2157,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
480,504749,1,3,9.0,104171110,2157,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
481,504749,1,3,10.0,26751596,2157,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
482,504749,1,3,11.0,26751596,2157,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
483,504749,1,3,12.0,104171110,2157,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
484,504749,1,3,13.0,26751596,2157,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
485,504749,1,3,14.0,104171110,2157,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
486,504749,1,3,15.0,26751596,2157,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
487,504749,1,3,16.0,26751596,2157,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
488,504749,1,3,17.0,26751596,2157,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
489,504749,1,3,18.0,26751596,2157,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
490,504749,1,3,19.0,26751596,2157,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
491,504749,1,3,20.0,104171110,2157,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
492,504749,1,3,21.0,26751596,2157,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
493,504749,1,3,22.0,104171110,2157,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
494,504749,1,3,23.0,104171110,2157,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
495,504749,1,3,24.0,26751596,2157,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
496,504749,1,3,25.0,26751596,2157,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
497,504749,1,3,26.0,26751596,2157,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
498,504749,1,3,27.0,104171110,2157,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
499,504749,1,3,28.0,104171110,2157,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
500,504749,1,3,29.0,26751596,2157,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
501,504749,1,3,30.0,104171110,2157,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
502,504749,1,3,31.0,104171110,2157,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
503,504749,1,3,32.0,26751596,2157,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
504,504749,1,3,33.0,104171110,2157,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
505,504749,1,3,34.0,26751596,2157,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
506,504749,1,3,35.0,26751596,2157,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
507,504749,1,3,36.0,104171110,2157,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
508,504749,1,3,37.0,26751596,2157,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
509,504749,1,3,38.0,104171110,2157,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
510,504749,1,3,39.0,26751596,2157,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
511,504749,1,3,40.0,26751596,2157,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
512,504749,1,3,41.0,104171110,2157,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
513,504749,1,3,42.0,26751596,2157,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
514,504749,1,3,43.0,26751596,2157,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
515,504749,1,3,44.0,26751596,2157,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
516,504749,1,3,45.0,104171110,2157,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
517,504749,1,3,46.0,26751596,2157,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
518,504749,1,3,47.0,26751596,2157,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
519,504749,1,3,48.0,26751596,2157,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
520,504749,1,3,49.0,26751596,2157,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
521,504749,1,3,50.0,104171110,2157,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
522,504749,1,3,51.0,26751596,2157,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
523,504749,1,3,52.0,26751596,2157,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
524,504749,1,3,53.0,104171110,2157,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
525,504749,1,3,54.0,26751596,2157,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
526,504749,1,3,55.0,104171110,2157,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
527,504749,1,3,56.0,26751596,2157,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
528,504749,1,3,57.0,26751596,2157,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
529,504749,1,3,58.0,26751596,2157,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
530,504749,1,3,59.0,104171110,2157,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
531,504749,1,3,60.0,104171110,2157,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
532,504749,1,3,61.0,26751596,2157,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
533,504810,1,2,,90341282,2157,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
534,504812,1,2,,90341282,2157,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
535,504832,1,1,,104171110,2157,Active,,,8.4921,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
536,504834,1,1,,104171110,2157,Active,,,6.7456,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
537,504836,1,2,,90341282,2157,Inactive,168984549.0,,,Potency,Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation,Confirmatory,11836247.0,
538,504845,1,1,,90341282,2157,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
539,504845,1,1,,104171110,2157,Inactive,86301163.0,5999.0,,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
540,504847,1,1,,11110785,2157,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
541,504847,1,1,,90341282,2157,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
542,504847,1,1,,104171110,2157,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
543,504865,1,1,,11110785,2157,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
544,504865,1,1,,90341282,2157,Inconclusive,118600387.0,7398.0,79.4328,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
545,504865,1,1,,104171110,2157,Inconclusive,118600387.0,7398.0,25.1189,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
546,513626,2,4,,103188875,2157,Active,,,,,Induction of autophagy in rat stable inducible PC12 cells expressing A53T alpha-synuclein assessed as A53T alpha-synuclein clearance at 1 uM after 24 hrs by densitometric analysis,Other,18391949.0,
547,513627,2,4,,103188875,2157,Active,,,,,Induction of autophagy in rat stable inducible PC12 cells expressing EGFP-HDQ74 assessed as soluble EGFP-HDQ74 clearance at 1 uM after 96 hrs by densitometric analysis,Other,18391949.0,
548,513628,1,4,,103188875,2157,Active,,,,,Induction of autophagy in human SK-N-MC cells expressing EGFP-HDQ74 assessed as reduction in EGFP-HDQ74 aggregation at 1 uM after 48 hrs by densitometric analysis,Other,18391949.0,
549,513629,1,4,,103188875,2157,Unspecified,,,,,Cytotoxicity against human SK-N-MC cells expressing EGFP-HDQ74 at 1 uM after 48 hrs,Other,18391949.0,
550,515780,5,1,,103188875,2157,Unspecified,,,,,Intrinsic solubility of the compound in water,Other,20810286.0,
551,540209,4,3,,103188875,2157,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,18426954.0,
552,540210,4,3,,103188875,2157,Unspecified,,,,,Clearance in human after iv administration,Other,18426954.0,
553,540211,2,5,,103188875,2157,Unspecified,,,,,Fraction unbound in human after iv administration,Other,18426954.0,
554,540212,4,3,,103188875,2157,Unspecified,,,,,Mean residence time in human after iv administration,Other,18426954.0,
555,540213,4,3,,103188875,2157,Unspecified,,,,,Half life in human after iv administration,Other,18426954.0,
556,540222,4,3,,103188875,2157,Unspecified,,,,,Clearance in rat after iv administration,Other,16621936.0,
557,540223,3,2,,103188875,2157,Unspecified,,,,,Volume of distribution at steady state in rat after iv administration,Other,16621936.0,
558,540224,4,3,,103188875,2157,Unspecified,,,,,Clearance in dog after iv administration,Other,16621936.0,
559,540225,4,3,,103188875,2157,Unspecified,,,,,Volume of distribution at steady state in dog after iv administration,Other,16621936.0,
560,540226,4,3,,103188875,2157,Unspecified,,,,,Clearance in monkey after iv administration,Other,16621936.0,
561,540227,4,3,,103188875,2157,Unspecified,,,,,Volume of distribution at steady state in monkey after iv administration,Other,16621936.0,
562,540228,4,3,,103188875,2157,Unspecified,,,,,Clearance in human after iv administration,Other,16621936.0,
563,540229,4,3,,103188875,2157,Unspecified,,,,,Volume of distribution at steady state in human after iv administration,Other,16621936.0,
564,540234,2,5,,103188875,2157,Unspecified,,,,,Cerep Phospholipidosis assay (HepG2 cells),Other,,
565,540236,2,3,,103188875,2157,Active,,,,,Phospholipidosis-positive literature compound observed in human,Other,17428028.0,
566,540237,2,3,,103188875,2157,Active,,,,,Phospholipidosis-positive literature compound observed in rat,Other,17428028.0,
567,540256,1,2,,90341282,2157,Active,,,20.5878,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
568,540276,1,2,,11110784,2157,Inconclusive,420597.0,,12.9953,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
569,540276,1,2,,11110785,2157,Inconclusive,420597.0,,12.9953,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
570,540276,1,2,,26751596,2157,Inconclusive,420597.0,,12.9953,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
571,540276,1,2,,26751597,2157,Inconclusive,420597.0,,12.9953,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
572,540276,1,2,,50100172,2157,Inconclusive,420597.0,,12.9953,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
573,540276,1,2,,90341282,2157,Inconclusive,420597.0,,23.0999,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
574,547621,4,3,,103188875,2157,Active,,,36.0,EC50,Cytotoxicity against BESM cells after 88 hrs by HTS assay,Confirmatory,20547819.0,
575,547622,4,2,,103188875,2157,Active,,,0.8,EC50,Antitrypanosomal activity against Trypanosoma cruzi amastigotes infected in BESM cells measured after 88 hrs postinfection by HTS assay,Confirmatory,20547819.0,
576,547804,1,3,,103188875,2157,Unspecified,,,,,"Selectivity window, ratio of EC50 for BESM cells to EC50 for Trypanosoma cruzi amastigotes infected in BESM cells",Other,20547819.0,
577,576612,7,5,,103188875,2157,Active,7531135.0,3757.0,1.0,IC50,Inhibition of human ERG,Confirmatory,21185626.0,
578,588208,2,3,,103188875,2157,Unspecified,,,,,Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset,Other,20799726.0,
579,588209,2,3,,103188875,2157,Unspecified,,,,,Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset,Other,20553011.0,
580,588210,2,4,,103188875,2157,Unspecified,,,,,Human drug-induced liver injury (DILI) modelling dataset from Ekins et al,Other,20843939.0,
581,588211,2,3,,103188875,2157,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
582,588212,2,3,,103188875,2157,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
583,588213,2,3,,103188875,2157,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
584,588214,2,3,,103188875,2157,Unspecified,,,,,"FDA HLAED, liver enzyme composite activity",Other,16472241.0,
585,588215,2,3,,103188875,2157,Unspecified,,,,,"FDA HLAED, alkaline phosphatase increase",Other,16472241.0,
586,588216,2,3,,103188875,2157,Unspecified,,,,,"FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase",Other,16472241.0,
587,588217,2,3,,103188875,2157,Unspecified,,,,,"FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase",Other,16472241.0,
588,588218,2,3,,103188875,2157,Unspecified,,,,,"FDA HLAED, lactate dehydrogenase (LDH) increase",Other,16472241.0,
589,588219,2,3,,103188875,2157,Unspecified,,,,,"FDA HLAED, gamma-glutamyl transferase (GGT) increase",Other,16472241.0,
590,588220,2,3,,103188875,2157,Unspecified,,,,,Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset,Other,20020916.0,
591,588349,1,1,,90341282,2157,Inconclusive,,,39.8107,Potency,qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay,Confirmatory,,
592,588378,1,1,,90341282,2157,Inconclusive,171543895.0,6311.0,22.3872,Potency,qHTS for Inhibitors of ATXN expression: Validation,Confirmatory,,
593,588453,1,1,,90341282,2157,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
594,588456,1,1,,90341282,2157,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
595,588519,1,2,,99300902,2157,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
596,588579,1,1,,11110785,2157,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
597,588579,1,1,,90341282,2157,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
598,588579,1,1,,104171110,2157,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
599,588579,1,1,,124879287,2157,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
600,588795,1,1,,90341282,2157,Inconclusive,4758356.0,2237.0,2.9935,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
601,588834,2,1,,26751596,2157,Active,325651834.0,3757.0,0.5012,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
602,589044,1,10,,103188875,2157,Unspecified,6686268.0,1559.0,,,"Clinically relevant inhibitors of human liver microsomal P450 enzymes, isoform CYP2C9",Other,,
603,589047,1,10,,103188875,2157,Unspecified,84028191.0,1565.0,,,"Clinically relevant inhibitors of human liver microsomal P450 enzymes, isoform CYP2D6",Other,,
604,589048,1,10,,103188875,2157,Unspecified,116241312.0,1576.0,,,"Clinically relevant inhibitors of human liver microsomal P450 enzymes, isoform CYP3A4",Other,,
605,589251,3,7,,103188875,2157,Unspecified,117225.0,1558.0,,Ki,Mechanism based inhibition of human cytochrome P450 2C8 measured by paclitaxel hydroxylation using human liver microsomes,Confirmatory,16248836.0,
606,589253,3,7,,103188875,2157,Unspecified,117225.0,1558.0,,Ki,Mechanism based inhibition of human cytochrome P450 2C8 measured by paclitaxel hydroxylation using a recombinant system,Confirmatory,16248836.0,
607,592682,1,4,,103188875,2157,Unspecified,,,,,Apparent permeability from apical to basolateral side of human Caco2 cells after 2 hrs by LC/MS/MS analysis,Other,21458999.0,
608,592683,1,4,,103188875,2157,Unspecified,,,,,Apparent permeability from basolateral side to apical side of human Caco2 cells by LC/MS/MS analysis,Other,21458999.0,
609,602314,1,2,,99300902,2157,Inactive,151220867.0,,,,A screen for compounds that modulate the activity of the Staphylococcus aureus MgrA protein,Other,,
610,602332,1,1,,11110785,2157,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
611,602332,1,1,,90341282,2157,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
612,602332,1,1,,104171110,2157,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
613,602332,1,1,,124879287,2157,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
614,602332,1,1,,124879290,2157,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
615,624030,1,2,,104171110,2157,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
616,624030,1,2,,124879290,2157,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
617,624031,1,2,,104171110,2157,Active,,,32.1968,Potency,S16 Schwann cell viability assay (CellTiter-Glo assay),Confirmatory,,
618,624032,1,2,,104171110,2157,Active,8393992.0,24660.0,28.6954,Potency,S16 Schwann cell PMP22 intronic element firefly luciferase assay,Confirmatory,,
619,624044,1,2,,104171110,2157,Inactive,8393992.0,24660.0,,Potency,S16 Schwann cell PMP22 intronic element beta-lactamase assay,Confirmatory,,
620,624146,1,1,,90341282,2157,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS): LOPAC Validation,Confirmatory,,
621,624147,1,1,,90341282,2157,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors: LOPAC Validation,Confirmatory,,
622,624148,1,2,,90341282,2157,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists: LOPAC Validation,Confirmatory,,
623,624149,1,1,,90341282,2157,Inactive,693842.0,4780.0,,Potency,qHTS of Nrf2 Activators: LOPAC Validation,Confirmatory,,
624,624170,1,1,,104171110,2157,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
625,624170,1,1,,124879290,2157,Inactive,71051501.0,2744.0,,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
626,624172,1,1,,104171110,2157,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
627,624172,1,1,,124879290,2157,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
628,624173,1,3,,104171110,2157,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
629,624173,1,3,,124879290,2157,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
630,624296,1,1,,26751596,2157,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
631,624296,1,1,,104171110,2157,Active,7705682.0,51053.0,12.9953,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
632,624297,1,1,,26751596,2157,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
633,624297,1,1,,104171110,2157,Active,7705682.0,51053.0,20.5962,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
634,624349,1,2,,92308723,2157,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
635,624455,1,1,,90341282,2157,Inactive,299681.0,1812.0,,Potency,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Hit Validation in HTRF,Confirmatory,,
636,625144,5,5,,103188875,2157,Unspecified,239977155.0,,,IC50,DRUGMATRIX: Leukotriene LTC4 Synthase enzyme inhibition (substrate: LTA4),Confirmatory,,
637,625145,4,7,,103188875,2157,Unspecified,20138087.0,10800.0,,IC50,DRUGMATRIX: Cysteinyl leukotriene receptor 1 radioligand binding (ligand: [3H]LTD4),Confirmatory,,
638,625146,5,5,,103188875,2157,Unspecified,126397.0,100009114.0,,IC50,DRUGMATRIX: Lipoxygenase 15-LO enzyme inhibition (substrate: Linoleic acid),Confirmatory,,
639,625147,4,7,,103188875,2157,Active,395398606.0,4159.0,12.372,IC50,DRUGMATRIX: Melanocortin MC3 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
640,625148,4,7,,103188875,2157,Active,60392672.0,4160.0,13.755,IC50,DRUGMATRIX: Melanocortin MC4 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
641,625149,4,7,,103188875,2157,Active,729996.0,4161.0,9.497,IC50,DRUGMATRIX: Melanocortin MC5 radioligand binding (ligand: [125I] NDP-alpha-MSH),Confirmatory,,
642,625150,5,5,,103188875,2157,Unspecified,113978.0,4128.0,,IC50,DRUGMATRIX: Monoamine Oxidase MAO-A enzyme inhibition (substrate: Kynuramine),Confirmatory,,
643,625151,4,7,,103188875,2157,Active,113118.0,1128.0,2.613,IC50,DRUGMATRIX: Muscarinic M1 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
644,625152,4,7,,103188875,2157,Active,113122.0,1129.0,5.08,IC50,DRUGMATRIX: Muscarinic M2 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
645,625153,4,7,,103188875,2157,Active,113125.0,1131.0,3.201,IC50,DRUGMATRIX: Muscarinic M3 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
646,625154,4,7,,103188875,2157,Active,23503039.0,1132.0,3.63,IC50,DRUGMATRIX: Muscarinic M4 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
647,625155,4,7,,103188875,2157,Active,543761.0,1133.0,1.499,IC50,DRUGMATRIX: Muscarinic M5 radioligand binding (ligand: [3H] N-Methylscopolamine),Confirmatory,,
648,625156,1,9,,103188875,2157,Unspecified,128997.0,4886.0,,,DRUGMATRIX: Neuropeptide Y Y1 radioligand binding (ligand: [125I] Peptide YY),Other,,
649,625157,6,2,,103188875,2157,Unspecified,1352610.0,4887.0,,IC50,DRUGMATRIX: Neuropeptide Y Y2 radioligand binding (ligand: [125I] Peptide YY),Confirmatory,,
650,625158,3,4,,103188875,2157,Unspecified,,,,IC50,DRUGMATRIX: Nicotinic Acetylcholine radioligand binding (ligand: [125I] Epibatidine),Confirmatory,,
651,625159,5,5,,103188875,2157,Unspecified,266646.0,24598.0,,IC50,"DRUGMATRIX: Nitric Oxide Synthase, Neuronal (nNOS) radioligand binding (ligand: [3H]L-Arginine)",Confirmatory,,
652,625160,1,9,,103188875,2157,Unspecified,266649.0,18126.0,,,"DRUGMATRIX: Nitric Oxide Synthase, Inducible (iNOS) enzyme inhibition (substrate: L-Arginine)",Other,,
653,625161,4,7,,103188875,2157,Active,311033488.0,4985.0,8.014,IC50,"DRUGMATRIX: Opiate delta1 (OP1, DOP) radioligand binding (ligand: [3H] Naltrindole)",Confirmatory,,
654,625162,4,7,,103188875,2157,Active,116242691.0,4986.0,16.68,IC50,"DRUGMATRIX: Opiate kappa (OP2, KOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
655,625163,4,7,,103188875,2157,Active,2851402.0,4988.0,19.037,IC50,"DRUGMATRIX: Opiate mu (OP3, MOP) radioligand binding (ligand: [3H] Diprenorphine)",Confirmatory,,
656,625164,1,6,,103188875,2157,Unspecified,,,,,DRUGMATRIX: Phorbol Ester radioligand binding (ligand: [3H] PDBu),Other,,
657,625165,3,4,,103188875,2157,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE3 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
658,625166,3,4,,103188875,2157,Unspecified,,,,IC50,DRUGMATRIX: Phosphodiesterase PDE4 enzyme inhibition (substrate: [3H]cAMP + cAMP),Confirmatory,,
659,625167,5,5,,103188875,2157,Unspecified,317373261.0,8654.0,,IC50,DRUGMATRIX: Phosphodiesterase PDE5 enzyme inhibition (substrate: [3H]cGMP + cGMP),Confirmatory,,
660,625168,4,7,,103188875,2157,Unspecified,129557.0,5724.0,,IC50,DRUGMATRIX: Platelet Activating Factor (PAF) radioligand binding (ligand: [3H] PAF),Confirmatory,,
661,625169,1,6,,103188875,2157,Unspecified,,,,,DRUGMATRIX: Platelet-Derived Growth Factor (PDGF) radioligand binding (ligand: [125I] PDGF),Other,,
662,625170,3,4,,103188875,2157,Unspecified,,,,IC50,DRUGMATRIX: Potassium Channel [KATP] radioligand binding (ligand: [3H] Glyburide),Confirmatory,,
663,625171,4,7,,103188875,2157,Unspecified,7531135.0,3757.0,,IC50,DRUGMATRIX: Potassium Channel HERG radioligand binding (ligand: [3H] Astemizole),Confirmatory,,
664,625172,4,7,,103188875,2157,Unspecified,75071465.0,,,IC50,DRUGMATRIX: Progesterone radioligand binding (ligand: [3H] R-5020),Confirmatory,,
665,625173,5,5,,103188875,2157,Unspecified,2822103.0,100009274.0,,IC50,"DRUGMATRIX: Peptidase, Angiotensin Converting Enzyme enzyme inhibition (substrate: FAPGG)",Confirmatory,,
666,625174,5,5,,103188875,2157,Unspecified,266321.0,834.0,,IC50,"DRUGMATRIX: Protease, Caspase 1 enzyme inhibition (substrate: Ac-YVAD-AMC)",Confirmatory,,
667,625175,5,5,,103188875,2157,Unspecified,115725.0,1511.0,,IC50,"DRUGMATRIX: Protease, Cathepsin G enzyme inhibition (substrate: Suc-Ala-Ala-Pro-Phe-AMC)",Confirmatory,,
668,625176,1,9,,103188875,2157,Unspecified,119292.0,1991.0,,,"DRUGMATRIX: Peptidase, ELA2 (Neutrophil Elastase 2) enzyme inhibition (substrate: N-MeOSuc-Ala-Ala-Pro-Val-pNA)",Other,,
669,625177,5,5,,103188875,2157,Unspecified,116852.0,4312.0,,IC50,"DRUGMATRIX: Peptidase, Matrix Metalloprotease-1 (MMP-1) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
670,625178,5,5,,103188875,2157,Unspecified,269849668.0,4318.0,,IC50,"DRUGMATRIX: Protease, Matrix Metalloprotease-9 (MMP-9) enzyme inhibition (substrate: Mca-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2)",Confirmatory,,
671,625179,1,9,,103188875,2157,Unspecified,317373571.0,5578.0,,,DRUGMATRIX: Protein Serine/Threonine Kinase PKCalpha enzyme inhibition (substrate: Histone),Other,,
672,625180,5,5,,103188875,2157,Unspecified,232066.0,5595.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK1 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
673,625181,5,5,,103188875,2157,Unspecified,119554.0,5594.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, ERK2 enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
674,625182,5,5,,103188875,2157,Unspecified,2499600.0,1432.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Kinase, p38alpha enzyme inhibition (substrate: Myelin Basic Protein)",Confirmatory,,
675,625183,5,5,,103188875,2157,Unspecified,1352673.0,5530.0,,IC50,"DRUGMATRIX: Protein Serine/Threonine Phosphatase, PPP3CA (Calcineurin, PP2B) enzyme inhibition (substrate: DiFMUP)",Confirmatory,,
676,625184,5,5,,103188875,2157,Unspecified,2811086.0,1956.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, EGF Receptor enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
677,625185,5,5,,103188875,2157,Active,125370.0,2534.0,0.8170000000000001,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, Fyn enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
678,625186,5,5,,103188875,2157,Active,119533.0,2064.0,9.148,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, ERBB2 (HER2) enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
679,625187,5,5,,103188875,2157,Unspecified,125474.0,3932.0,,IC50,"DRUGMATRIX: Protein Tyrosine Kinase, LCK enzyme inhibition (substrate: Poly(Glu:Tyr))",Confirmatory,,
680,625188,1,9,,103188875,2157,Unspecified,33112650.0,5788.0,,,"DRUGMATRIX: Protein Tyrosine Phosphatase, PTPRC (CD45) enzyme inhibition (substrate: DiFMUP)",Other,,
681,625189,1,7,,103188875,2157,Unspecified,,,,,"DRUGMATRIX: Purinergic P2X radioligand binding (ligand: [3H] alpha, beta-Methylene-ATP)",Other,,
682,625190,4,5,,103188875,2157,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1A radioligand binding (ligand: [3H] 8-OH-DPAT),Confirmatory,,
683,625191,4,7,,103188875,2157,Unspecified,112815.0,25075.0,86.167,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT1B radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
684,625192,4,7,,103188875,2157,Active,543727.0,3356.0,3.59,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2A radioligand binding (ligand: [3H] Ketanserin),Confirmatory,,
685,625193,5,5,,103188875,2157,Unspecified,113037.0,43.0,,IC50,DRUGMATRIX: Acetylcholinesterase enzyme inhibition (substrate: acetylthiocholine),Confirmatory,,
686,625194,4,7,,103188875,2157,Unspecified,231473.0,134.0,,IC50,DRUGMATRIX: Adenosine A1 radioligand binding (ligand: DPCPX),Confirmatory,,
687,625195,4,7,,103188875,2157,Unspecified,543740.0,135.0,,IC50,DRUGMATRIX: Adenosine A2A radioligand binding (ligand: AB-MECA),Confirmatory,,
688,625196,5,6,,103188875,2157,Active,803374855.0,140.0,17.547,IC50,DRUGMATRIX: Adenosine A3 radioligand binding (ligand: AB-MECA),Confirmatory,,
689,625197,3,4,,103188875,2157,Unspecified,,,,IC50,DRUGMATRIX: Sodium/nucleoside co-transporter radioligand binding (ligand: nitrobenzylthioinosine),Confirmatory,,
690,625198,4,7,,103188875,2157,Unspecified,1168247.0,29412.0,,IC50,DRUGMATRIX: Alpha-1A adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
691,625199,4,7,,103188875,2157,Unspecified,543734.0,24173.0,,IC50,DRUGMATRIX: Alpha-1B adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
692,625200,4,7,,103188875,2157,Unspecified,1168243.0,146.0,,IC50,DRUGMATRIX: Alpha-1D adrenergic receptor radioligand binding (ligand: prazosin),Confirmatory,,
693,625201,4,7,,103188875,2157,Active,1351829.0,150.0,0.312,IC50,DRUGMATRIX: Alpha-2A adrenergic receptor radioligand binding (ligand: MK-912),Confirmatory,,
694,625202,4,7,,103188875,2157,Active,613504690.0,151.0,12.892999999999999,IC50,DRUGMATRIX: Alpha-2B adrenergic receptor radioligand binding (ligand: Rauwolscine),Confirmatory,,
695,625203,4,7,,103188875,2157,Unspecified,20141211.0,152.0,,IC50,DRUGMATRIX: Adrenergic Alpha-2C radioligand binding (ligand: [3H] MK-912),Confirmatory,,
696,625204,4,7,,103188875,2157,Active,48429211.0,153.0,43.643,IC50,DRUGMATRIX: Adrenergic beta1 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
697,625205,4,7,,103188875,2157,Unspecified,296439450.0,154.0,,IC50,DRUGMATRIX: Adrenergic beta2 radioligand binding (ligand: [3H] CGP-12177),Confirmatory,,
698,625206,4,7,,103188875,2157,Active,461604.0,155.0,42.349,IC50,DRUGMATRIX: Adrenergic beta3 radioligand binding (ligand: [125I] Cyanopindolol),Confirmatory,,
699,625207,4,7,,103188875,2157,Active,128616.0,6530.0,2.271,IC50,DRUGMATRIX: Norepinephrine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
700,625208,5,5,,103188875,2157,Unspecified,1168407.0,24192.0,,IC50,DRUGMATRIX: Aldose Reductase enzyme inhibition (substrate: DL-Glyceraldehyde),Confirmatory,,
701,625209,4,7,,103188875,2157,Unspecified,1703214.0,186.0,,IC50,DRUGMATRIX: Angiotensin AT2 radioligand binding (ligand: [125I] CGP-42112A),Confirmatory,,
702,625210,3,4,,103188875,2157,Unspecified,,,,IC50,"DRUGMATRIX: ATPase, Na+/K+ enzyme inhibition (substrate: ATP)",Confirmatory,,
703,625211,1,6,,103188875,2157,Unspecified,,,,,DRUGMATRIX: Atrial Natriuretic Factor (ANF) radioligand binding (ligand: [125I] ANF (rat)),Other,,
704,625212,3,4,,103188875,2157,Unspecified,,,,IC50,DRUGMATRIX: beta-Lactamase enzyme inhibition (substrate: Nitrocefin),Confirmatory,,
705,625213,4,7,,103188875,2157,Active,2506481.0,624.0,12.966,IC50,DRUGMATRIX: Bradykinin B2 radioligand binding (ligand: [3H] Bradykinin),Confirmatory,,
706,625214,1,9,,103188875,2157,Unspecified,550544247.0,799.0,,,DRUGMATRIX: Calcitonin radioligand binding (ligand: [125I] Calcitonin (salmon)),Other,,
707,625215,3,4,,103188875,2157,Active,,,0.054000000000000006,IC50,"DRUGMATRIX: Calcium Channel Type L, Benzothiazepine radioligand binding (ligand: [3H] Diltiazem)",Confirmatory,,
708,625216,3,4,,103188875,2157,Active,,,0.165,IC50,"DRUGMATRIX: Calcium Channel Type L, Dihydropyridine radioligand binding (ligand: [3H] Nitrendipine)",Confirmatory,,
709,625217,4,7,,103188875,2157,Active,1168220.0,3357.0,0.9229999999999999,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2B radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
710,625218,4,7,,103188875,2157,Active,112816.0,3358.0,0.40399999999999997,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT2C radioligand binding (ligand: [3H] Mesulergine),Confirmatory,,
711,625219,3,4,,103188875,2157,Unspecified,,,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT3 radioligand binding (ligand: [3H] GR-65630),Confirmatory,,
712,625220,4,7,,103188875,2157,Unspecified,6224984.0,100135548.0,,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT4 radioligand binding (ligand: [3H] GR-113808),Confirmatory,,
713,625221,4,7,,103188875,2157,Active,1703010.0,3362.0,19.441,IC50,DRUGMATRIX: Serotonin (5-Hydroxytryptamine) 5-HT6 radioligand binding (ligand: [3H] Lysergic acid diethylamide),Confirmatory,,
714,625222,4,7,,103188875,2157,Active,400630.0,6532.0,2.305,IC50,"DRUGMATRIX: Transporter, Serotonin (5-Hydroxytryptamine) (SERT) radioligand binding (ligand: [3H] Paroxetine)",Confirmatory,,
715,625223,4,7,,103188875,2157,Active,74752153.0,10280.0,0.09699999999999999,IC50,DRUGMATRIX: Sigma1 radioligand binding (ligand: [3H] Haloperidol),Confirmatory,,
716,625224,3,4,,103188875,2157,Active,,,0.11699999999999999,IC50,DRUGMATRIX: Sigma2 radioligand binding (ligand: [3H] Ifenprodil),Confirmatory,,
717,625225,3,4,,103188875,2157,Active,,,0.6629999999999999,IC50,"DRUGMATRIX: Sodium Channel, Site 2 radioligand binding (ligand: [3H] Batrachotoxin)",Confirmatory,,
718,625226,4,7,,103188875,2157,Unspecified,128359.0,6869.0,,IC50,DRUGMATRIX: Tachykinin NK1 radioligand binding (ligand: [3H] Substance P),Confirmatory,,
719,625227,4,7,,103188875,2157,Active,229462950.0,6865.0,19.315,IC50,DRUGMATRIX: Tachykinin NK2 radioligand binding (ligand: [3H] SR-48968),Confirmatory,,
720,625228,4,7,,103188875,2157,Active,113832.0,24208.0,42.248000000000005,IC50,DRUGMATRIX: Androgen (Testosterone) AR radioligand binding (ligand: [3H] Mibolerone),Confirmatory,,
721,625229,5,5,,103188875,2157,Unspecified,254763392.0,6916.0,,IC50,DRUGMATRIX: Thromboxane Synthetase enzyme inhibition (substrate: PGH2),Confirmatory,,
722,625230,1,6,,103188875,2157,Unspecified,,,,,"DRUGMATRIX: Tumor Necrosis Factor (TNF), Non-Selective radioligand binding (ligand: [125I] TNF-alpha)",Other,,
723,625231,4,7,,103188875,2157,Unspecified,143811474.0,2321.0,,IC50,DRUGMATRIX: Vascular Endothelial Growth Factor (VEGF) radioligand binding (ligand: [125I] VEGF),Confirmatory,,
724,625232,1,9,,103188875,2157,Unspecified,418253.0,7433.0,,,DRUGMATRIX: Vasoactive Intestinal Peptide VIP1 radioligand binding (ligand: [125I] VIP),Other,,
725,625233,4,7,,103188875,2157,Unspecified,586197.0,552.0,,IC50,DRUGMATRIX: Vasopressin V1A radioligand binding (ligand: [125I] PhenylacetylTyr(Me)PheGlnAsnArgProArgTyr),Confirmatory,,
726,625234,3,4,,103188875,2157,Active,,,0.539,IC50,"DRUGMATRIX: Calcium Channel Type L, Phenylalkylamine radioligand binding (ligand: [3H] (-)-Desmethoxyverapamil (D-888))",Confirmatory,,
727,625235,4,7,,103188875,2157,Unspecified,115562.0,1268.0,,IC50,DRUGMATRIX: Cannabinoid CB1 radioligand binding (ligand: [3H] SR141716A),Confirmatory,,
728,625236,5,5,,103188875,2157,Unspecified,115456.0,760.0,,IC50,DRUGMATRIX: Carbonic Anhydrase II enzyme inhibition (substrate: 4-Nitrophenyl acetate (4-NPA)),Confirmatory,,
729,625237,4,7,,103188875,2157,Active,1168965.0,729230.0,11.085999999999999,IC50,DRUGMATRIX: Chemokine CCR2B radioligand binding (ligand: [125I] MCP-1),Confirmatory,,
730,625238,4,7,,103188875,2157,Active,1705894.0,1233.0,21.773000000000003,IC50,DRUGMATRIX: Chemokine CCR4 radioligand binding (ligand: [125I] TARC),Confirmatory,,
731,625239,4,7,,103188875,2157,Unspecified,1705896.0,1234.0,,IC50,DRUGMATRIX: Chemokine CCR5 radioligand binding (ligand: [125I] MIP-1alpha),Confirmatory,,
732,625240,1,9,,103188875,2157,Unspecified,108936015.0,3577.0,,,DRUGMATRIX: Chemokine CXCR1 (IL-8A),Other,,
733,625241,4,7,,103188875,2157,Unspecified,1352454.0,3579.0,,IC50,DRUGMATRIX: Chemokine CXCR2 (IL-8B) radioligand binding (ligand: [125I] IL-8),Confirmatory,,
734,625242,4,7,,103188875,2157,Unspecified,416772.0,886.0,,IC50,"DRUGMATRIX: Cholecystokinin CCKA radioligand binding (ligand: [3H] L-364,718)",Confirmatory,,
735,625243,5,5,,103188875,2157,Unspecified,317373262.0,5742.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-1 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
736,625244,5,5,,103188875,2157,Unspecified,3915797.0,5743.0,,IC50,DRUGMATRIX: Cyclooxygenase COX-2 enzyme inhibition (substrate: Arachidonic acid),Confirmatory,,
737,625245,5,5,,103188875,2157,Unspecified,117144.0,1544.0,,IC50,"DRUGMATRIX: CYP450, 1A2 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
738,625246,1,9,,103188875,2157,Unspecified,308153612.0,1548.0,,,"DRUGMATRIX: CYP450, 2A6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Other,,
739,625247,5,5,,103188875,2157,Unspecified,60416369.0,1557.0,,IC50,"DRUGMATRIX: CYP450, 2C19 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
740,625248,5,5,,103188875,2157,Unspecified,6686268.0,1559.0,,IC50,"DRUGMATRIX: CYP450, 2C9 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
741,625249,5,5,,103188875,2157,Unspecified,84028191.0,1565.0,,IC50,"DRUGMATRIX: CYP450, 2D6 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
742,625250,5,5,,103188875,2157,Unspecified,117250.0,1571.0,,IC50,"DRUGMATRIX: CYP450, 2E1 enzyme inhibition (substrate: 3-Cyano-7-ethoxycoumarin)",Confirmatory,,
743,625251,5,5,,103188875,2157,Unspecified,116241312.0,1576.0,,IC50,"DRUGMATRIX: CYP450, 3A4 enzyme inhibition (substrate: 7-Benzyloxy-4-(trifluoromethyl)-coumarin)",Confirmatory,,
744,625252,4,7,,103188875,2157,Active,118228.0,1812.0,9.142000000000001,IC50,DRUGMATRIX: Dopamine D1 radioligand binding (ligand: [3H] SCH-23390),Confirmatory,,
745,625253,4,7,,103188875,2157,Active,118206.0,1813.0,19.952,IC50,DRUGMATRIX: Dopamine D2L radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
746,625254,4,7,,103188875,2157,Active,1169206.0,1814.0,1.208,IC50,DRUGMATRIX: Dopamine D3 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
747,625255,4,7,,103188875,2157,Active,1345939.0,1815.0,17.72,IC50,DRUGMATRIX: Dopamine D4.2 radioligand binding (ligand: [3H] Spiperone),Confirmatory,,
748,625256,4,7,,103188875,2157,Active,266667.0,6531.0,2.505,IC50,DRUGMATRIX: Dopamine Transporter radioligand binding (ligand: [125I] RTI-55),Confirmatory,,
749,625257,4,7,,103188875,2157,Active,119606.0,1909.0,26.288,IC50,DRUGMATRIX: Endothelin ETA radioligand binding (ligand: [125I] Endothelin-1),Confirmatory,,
750,625258,4,7,,103188875,2157,Unspecified,544257.0,2099.0,,IC50,DRUGMATRIX: Estrogen ERalpha radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
751,625259,4,7,,103188875,2157,Unspecified,6166154.0,2100.0,,IC50,DRUGMATRIX: Estrogen ERbeta radioligand binding (ligand: [3H] Estradiol),Confirmatory,,
752,625260,3,4,,103188875,2157,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Muscimol, Central radioligand binding (ligand: [3H] Muscimol)",Confirmatory,,
753,625261,3,4,,103188875,2157,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Flunitrazepam, Central radioligand binding (ligand: [3H] Flunitrazepam)",Confirmatory,,
754,625262,3,4,,103188875,2157,Unspecified,,,,IC50,"DRUGMATRIX: GABAA, Chloride Channel, TBOB radioligand binding (ligand: [3H] TBOB)",Confirmatory,,
755,625263,4,7,,103188875,2157,Unspecified,121069.0,2908.0,,IC50,DRUGMATRIX: Glucocorticoid radioligand binding (ligand: [3H] Dexamethasone),Confirmatory,,
756,625264,3,4,,103188875,2157,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, AMPA radioligand binding (ligand: [3H] AMPA)",Confirmatory,,
757,625265,1,6,,103188875,2157,Unspecified,,,,,"DRUGMATRIX: Glutamate, Kainate radioligand binding (ligand: [3H] Kainic acid)",Other,,
758,625266,3,4,,103188875,2157,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Agonism radioligand binding (ligand: [3H] CGP-39653)",Confirmatory,,
759,625267,3,4,,103188875,2157,Unspecified,,,,IC50,"DRUGMATRIX: Glutamate, NMDA, Phencyclidine radioligand binding (ligand: [3H] TCP)",Confirmatory,,
760,625268,4,2,,103188875,2157,Unspecified,121579.0,24397.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
761,625268,4,2,,103188875,2157,Unspecified,121580.0,114516.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
762,625268,4,2,,103188875,2157,Unspecified,121604.0,25456.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
763,625268,4,2,,103188875,2157,Unspecified,12230887.0,25674.0,,IC50,"DRUGMATRIX: Glycine, Strychnine-Sensitive radioligand binding (ligand: [3H] Strychnine)",Confirmatory,,
764,625269,4,7,,103188875,2157,Unspecified,547645.0,3269.0,,IC50,"DRUGMATRIX: Histamine H1, Central radioligand binding (ligand: [3H] Pyrilamine)",Confirmatory,,
765,625270,4,7,,103188875,2157,Active,123120.0,3274.0,10.555,IC50,DRUGMATRIX: Histamine H2 radioligand binding (ligand: [125I] Aminopotentidine),Confirmatory,,
766,625271,5,5,,103188875,2157,Unspecified,123343.0,3156.0,,IC50,DRUGMATRIX: HMG-CoA Reductase enzyme inhibition (substrate: [14C]HMG-CoA),Confirmatory,,
767,625272,3,4,,103188875,2157,Active,,,7.8260000000000005,IC50,"DRUGMATRIX: Imidazoline I2, Central radioligand binding (ligand: [3H] Idazoxan)",Confirmatory,,
768,625273,4,6,,103188875,2157,Unspecified,124531.0,24954.0,,IC50,DRUGMATRIX: Insulin radioligand binding (ligand: [125I] Insulin),Confirmatory,,
769,625274,1,6,,103188875,2157,Unspecified,,,,,DRUGMATRIX: Interleukin IL-1 radioligand binding (ligand: [125I] interleukin 1beta),Other,,
770,625275,3,4,,103188875,2157,Unspecified,,,,IC50,"DRUGMATRIX: Leukotriene, BLT (LTB4) radioligand binding (ligand: [3H]LTB4)",Confirmatory,,
771,625276,1,3,,103188875,2157,Unspecified,,,,,FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of most concern for DILI,Other,21624500.0,
772,625279,1,3,,103188875,2157,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia,Other,22194678.0,
773,625280,1,3,,103188875,2157,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis,Other,22194678.0,
774,625281,1,3,,103188875,2157,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis,Other,22194678.0,
775,625282,1,3,,103188875,2157,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis,Other,22194678.0,
776,625283,1,3,,103188875,2157,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests,Other,22194678.0,
777,625284,1,3,,103188875,2157,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure,Other,22194678.0,
778,625285,1,3,,103188875,2157,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis,Other,22194678.0,
779,625286,1,3,,103188875,2157,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis,Other,22194678.0,
780,625287,1,3,,103188875,2157,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly,Other,22194678.0,
781,625288,1,3,,103188875,2157,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice,Other,22194678.0,
782,625289,1,3,,103188875,2157,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease,Other,22194678.0,
783,625290,1,3,,103188875,2157,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty,Other,22194678.0,
784,625291,1,3,,103188875,2157,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal,Other,22194678.0,
785,625292,1,3,,103188875,2157,Unspecified,,,,,Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score,Other,22194678.0,
786,643383,1,6,,103188875,2157,Unspecified,,,,,Induction of phospholipidosis in bovine corneal fibroblasts assessed as lamellar inclusion bodies after 72 hrs by light microscopy,Other,22122484.0,
787,651631,4,1,,144203634,2157,Inconclusive,269849759.0,7157.0,29.8493,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
788,651632,4,1,,144203634,2157,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
789,651633,4,1,,144203634,2157,Active,,,26.6032,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
790,651634,4,1,,144203634,2157,Inconclusive,,,29.8493,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
791,651635,1,3,,11110785,2157,Inconclusive,171543895.0,6311.0,11.2202,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
792,651635,1,3,,90341282,2157,Inconclusive,171543895.0,6311.0,39.8107,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
793,651828,1,2,,92308723,2157,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
794,652048,1,2,,144203634,2157,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
795,652051,1,1,,144203634,2157,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
796,652106,1,1,,90341282,2157,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
797,655930,1,5,,103188875,2157,Unspecified,,,,,Antiarrhythmic activity in guinea pig left atria assessed as increase of 1 Hz-induced alternating current arrhythmia at 10'-4 M after 60 mins relative to control,Other,22191686.0,
798,655932,1,5,,103188875,2157,Unspecified,,,,,Negative inotropic activity in guinea pig left atria assessed as decrease of 1 Hz current-induced developed tension at 10'-4 M relative to control,Other,22191686.0,
799,655937,1,5,,103188875,2157,Unspecified,,,,,Negative chronotropic activity in guinea pig spontaneously beating right atria assessed as decrease in atrial rate at 10'-4 M relative to control,Other,22191686.0,
800,655941,1,5,,103188875,2157,Active,,,,,Negative chronotropic activity in guinea pig spontaneously beating right atria assessed as decrease in atrial rate,Other,22191686.0,
801,655942,1,3,,103188875,2157,Unspecified,,,,,Vasorelaxant activity in potassium depolarized guinea pig aortic strip assessed as inhibition of calcium-induced contraction at 10'-4 M,Other,22191686.0,
802,678712,1,8,,103188875,2157,Active,117144.0,1544.0,,,Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins,Other,22931300.0,
803,678713,1,8,,103188875,2157,Active,6686268.0,1559.0,,,Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins,Other,22931300.0,
804,678714,1,8,,103188875,2157,Active,60416369.0,1557.0,,,Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
805,678715,1,8,,103188875,2157,Unspecified,84028191.0,1565.0,,,Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins,Other,22931300.0,
806,678716,1,8,,103188875,2157,Unspecified,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins,Other,22931300.0,
807,678717,1,8,,103188875,2157,Unspecified,116241312.0,1576.0,,,Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins,Other,22931300.0,
808,678721,1,5,,103188875,2157,Active,,,,,Metabolic stability in human liver microsomes assessed as GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis,Other,22931300.0,
809,678722,1,5,,103188875,2157,Inconclusive,,,,,Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH,Other,22931300.0,
810,678838,3,6,,103188875,2157,Unspecified,238054374.0,5243.0,12.8,EC50,TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation (Calcein-AM: 0.25 uM) in MDR-CEM cells,Confirmatory,8862725.0,
811,679131,3,6,,103188875,2157,Unspecified,238054374.0,5243.0,45.6,IC50,TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical) (Digoxin: 0.025 uM) in MDR1-expressing LLC-PK1 cells,Confirmatory,11231118.0,
812,679132,3,6,,103188875,2157,Unspecified,238054374.0,5243.0,22.5,IC50,TP_TRANSPORTER: inhibition of Daunorubicin transepithelial transport (basal to apical) (Daunorubicin: 0.035 uM) in MDR1-expressing LLC-PK1 cells,Confirmatory,11231118.0,
813,679577,1,8,,103188875,2157,Unspecified,238054374.0,5243.0,,,"TP_TRANSPORTER: inhibition of Digoxin transepithelial transport (basal to apical)(Digoxin: 5 uM, Amiodarone: 100 uM) in Caco-2 cells",Other,10213372.0,
814,679750,3,6,,103188875,2157,Unspecified,238054374.0,5243.0,5.78,Ki,TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation in MDR1-expressing LLC-PK1 cells,Confirmatory,12235267.0,
815,681137,3,6,,103188875,2157,Unspecified,239938877.0,18671.0,2.1,Ki,TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation in mdr1a-expressing LLC-PK1 cells,Confirmatory,12235267.0,
816,681138,3,6,,103188875,2157,Unspecified,126927.0,18669.0,12.7,Ki,TP_TRANSPORTER: increase in Calcein-AM intracellular accumulation in mdr1b-expressing LLC-PK1 cells,Confirmatory,12235267.0,
817,681166,1,8,,103188875,2157,Unspecified,238054374.0,5243.0,,,"TP_TRANSPORTER: Western blot, LS180 cell",Other,8632764.0,
818,681844,2,7,,103188875,2157,Unspecified,3914190.0,170698.0,1.8,Ki,TP_TRANSPORTER: inhibition of Digoxin uptake in Xenopus laevis oocytes,Confirmatory,11316767.0,
819,686977,2,1,,49698843,2157,Inactive,9657203.0,2615631.0,,IC50,Vibrio cholerae assay for pro-quorum sensing small molecules,Confirmatory,,
820,686978,1,1,,124879287,2157,Inconclusive,79154014.0,55775.0,24.0881,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
821,686978,1,1,,144203634,2157,Inconclusive,79154014.0,55775.0,26.6086,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
822,686979,1,1,,124879287,2157,Inconclusive,79154014.0,55775.0,12.0726,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
823,686979,1,1,,144203634,2157,Inconclusive,79154014.0,55775.0,33.4983,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
824,719671,2,2,,103188875,2157,Unspecified,,,100.0,IC50,Inhibition of rat FAO,Confirmatory,21504156.0,
825,719672,2,2,,103188875,2157,Active,,,16.6,IC50,Cytotoxicity in human KB cells,Confirmatory,21504156.0,
826,719673,2,2,,103188875,2157,Active,,,28.5,IC50,Inhibition of human FAO,Confirmatory,21504156.0,
827,719674,3,5,,103188875,2157,Unspecified,416836.0,1376.0,100.0,IC50,Inhibition of human CPT2,Confirmatory,21504156.0,
828,719719,3,5,,103188875,2157,Unspecified,2493497.0,1375.0,100.0,IC50,Inhibition of human CPT1B,Confirmatory,21504156.0,
829,719720,3,5,,103188875,2157,Unspecified,56405343.0,1374.0,140.0,IC50,Inhibition of human CPT1A,Confirmatory,21504156.0,
830,720516,2,1,,144203634,2157,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
831,720532,1,1,,11110785,2157,Inconclusive,420597.0,,2.2387,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
832,720532,1,1,,124879287,2157,Active,420597.0,,11.2202,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
833,720532,1,1,,144203634,2157,Active,420597.0,,7.9433,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
834,720533,1,1,,11110785,2157,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
835,720533,1,1,,124879287,2157,Inconclusive,,,25.1189,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
836,720533,1,1,,144203634,2157,Active,,,22.3872,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
837,720538,1,2,,90341282,2157,Inactive,220983390.0,410.0,,Potency,qHTS screen for enhancers of Arylsulfatase A (ASA1): LOPAC Validation Assay,Confirmatory,,
838,720552,2,1,,144203634,2157,Inconclusive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
839,720559,1,2,,90341282,2157,Inactive,112927.0,351.0,,Potency,qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: LOPAC Validation Assay,Confirmatory,,
840,720572,1,2,,90341282,2157,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (NLuc Reporter),Confirmatory,,
841,720573,1,2,,90341282,2157,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (FLuc Reporter),Confirmatory,,
842,720579,2,1,,124879287,2157,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
843,720580,1,1,,124879287,2157,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
844,720634,2,1,,144203634,2157,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
845,720635,2,1,,144203634,2157,Inconclusive,,,8.4127,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
846,720637,2,1,,144203634,2157,Inconclusive,,,10.1922,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
847,720641,1,2,,92308723,2157,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
848,720674,2,2,,144203634,2157,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
849,720675,2,2,,144203634,2157,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
850,720678,2,1,,144203634,2157,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
851,720679,2,1,,144203634,2157,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
852,720680,2,1,,144203634,2157,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
853,720681,2,1,,144203634,2157,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
854,720682,2,1,,144203634,2157,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
855,720683,2,1,,144203634,2157,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
856,720684,2,1,,144203634,2157,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
857,720685,2,1,,144203634,2157,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
858,720686,2,1,,144203634,2157,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
859,720687,2,2,,144203634,2157,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
860,720691,4,1,,144203634,2157,Inconclusive,311348376.0,2908.0,26.8325,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
861,720692,3,1,,144203634,2157,Inconclusive,311348376.0,2908.0,26.8325,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
862,720693,3,1,,144203634,2157,Inconclusive,,,26.8325,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
863,720717,1,3,,92308723,2157,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
864,720717,1,3,,92309990,2157,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
865,720719,2,1,,144203634,2157,Inconclusive,311348376.0,2908.0,28.4224,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
866,720725,2,1,,144203634,2157,Inconclusive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
867,730881,1,3,,103188875,2157,Unspecified,,,,,Drug uptake in human urine,Other,23145854.0,
868,730882,1,2,,103188875,2157,Unspecified,,,,,Elimination half life in human,Other,23145854.0,
869,743012,3,1,,144203634,2157,Active,,,6.6824,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
870,743014,3,1,,144203634,2157,Active,,,5.9557,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
871,743015,3,1,,144203634,2157,Active,,,8.4127,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
872,743033,3,1,,144203634,2157,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
873,743035,2,1,,144203634,2157,Inconclusive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
874,743036,2,1,,144203634,2157,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
875,743040,3,1,,144203634,2157,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
876,743041,3,1,,144203634,2157,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
877,743042,3,1,,144203634,2157,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
878,743053,2,1,,144203634,2157,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
879,743054,2,1,,144203634,2157,Inactive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
880,743063,2,1,,144203634,2157,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
881,743064,3,1,,144203634,2157,Active,,,13.3332,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
882,743065,3,1,,144203634,2157,Active,399498506.0,24831.0,16.7855,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
883,743066,3,1,,144203634,2157,Inconclusive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
884,743067,2,1,,144203634,2157,Inconclusive,399498506.0,24831.0,19.5704,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
885,743069,2,1,,144203634,2157,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
886,743074,2,1,,144203634,2157,Inconclusive,,,18.9959,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
887,743075,2,1,,144203634,2157,Inactive,348019627.0,2099.0,30.1065,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
888,743077,2,1,,144203634,2157,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
889,743078,2,1,,144203634,2157,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
890,743079,3,1,,144203634,2157,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
891,743080,3,1,,144203634,2157,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
892,743081,3,1,,144203634,2157,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
893,743083,3,1,,144203634,2157,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
894,743084,3,1,,144203634,2157,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
895,743085,3,1,,144203634,2157,Inactive,51095037.0,196.0,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
896,743086,3,1,,144203634,2157,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
897,743091,2,1,,144203634,2157,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
898,743094,3,1,,144203634,2157,Inconclusive,216409692.0,5468.0,23.9145,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
899,743122,2,1,,144203634,2157,Inactive,51095037.0,196.0,,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
900,743139,2,1,,144203634,2157,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
901,743140,2,1,,144203634,2157,Inconclusive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
902,743191,3,1,,170464920,2157,Inconclusive,216409692.0,5468.0,33.4889,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
903,743194,3,1,,170464920,2157,Inconclusive,,,2.113,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
904,743199,2,1,,170464920,2157,Inconclusive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
905,743202,4,1,,170464920,2157,Inconclusive,20149576.0,4780.0,5.9553,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
906,743203,3,1,,170464920,2157,Inconclusive,,,33.4889,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
907,743205,1,1,,90341282,2157,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
908,743205,1,1,,90341282,2157,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
909,743206,1,1,,90341282,2157,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
910,743206,1,1,,90341282,2157,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
911,743207,1,1,,90341282,2157,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
912,743207,1,1,,90341282,2157,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
913,743209,3,1,,170464920,2157,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
914,743210,4,1,,170464920,2157,Inconclusive,4504517.0,3315.0,23.7083,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
915,743211,3,1,,170464920,2157,Active,,,16.7842,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
916,743212,3,1,,170464920,2157,Inconclusive,216409690.0,5467.0,10.5901,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
917,743213,3,1,,170464920,2157,Active,,,23.7083,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
918,743215,3,1,,170464920,2157,Inconclusive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
919,743217,3,1,,170464920,2157,Inconclusive,325495553.0,9971.0,29.846999999999998,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
920,743218,3,1,,170464920,2157,Active,,,18.8322,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
921,743219,3,1,,170464920,2157,Inactive,20149576.0,4780.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
922,743220,3,1,,170464920,2157,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
923,743221,3,1,,170464920,2157,Active,,,29.846999999999998,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
924,743222,3,1,,170464920,2157,Inconclusive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
925,743223,3,1,,170464920,2157,Inactive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
926,743224,3,1,,170464920,2157,Active,,,26.6011,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
927,743225,3,1,,170464920,2157,Active,,,23.9145,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
928,743226,2,1,,170464920,2157,Inconclusive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
929,743227,2,1,,170464920,2157,Inconclusive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
930,743228,3,1,,170464920,2157,Inconclusive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
931,743239,2,1,,170464920,2157,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
932,743240,2,1,,170464920,2157,Inconclusive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
933,743241,2,1,,170464920,2157,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
934,743242,2,1,,170464920,2157,Inconclusive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
935,743244,1,1,,90341282,2157,Inconclusive,,,1.2589,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
936,743244,1,1,,144203634,2157,Inconclusive,,,22.3872,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
937,743344,1,1,,124879289,2157,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (3D7) proliferation,Confirmatory,,
938,743345,1,1,,124879289,2157,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation,Confirmatory,,
939,743346,1,1,,124879289,2157,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (DD2) proliferation (Rep 2),Confirmatory,,
940,743347,1,1,,124879289,2157,Inactive,,,,Potency,qHTS profiling of the MIPE4 collection as inhibitors of Plasmodium falciparum (HB3) proliferation,Confirmatory,,
941,781326,1,2,,103188875,2157,Unspecified,,,,,pKa (acid-base dissociation constant) as determined by Avdeef ref: DOI: 10.1002/047145026X,Other,24249037.0,
942,782667,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Pathology; Tissue: Liver; Assay: Cellular Infiltration; Study_ID: 209/5,Other,,
943,782668,1,2,,103188875,2157,Unspecified,,,,,"Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Pathology; Tissue: Kidney; Assay: Renal Tubule, Regeneration; Study_ID: 209/5",Other,,
944,782669,1,2,,103188875,2157,Unspecified,,,,,"Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Pathology; Tissue: Kidney; Assay: Renal Tubule, Regeneration; Study_ID: 209/6",Other,,
945,782670,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Pathology; Tissue: Liver; Assay: Cellular Infiltration; Study_ID: 209/6,Other,,
946,782671,1,2,,103188875,2157,Unspecified,,,,,"Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Pathology; Tissue: Kidney; Assay: Renal Tubule, Dilatation, Cystic; Study_ID: 209/6",Other,,
947,782672,1,2,,103188875,2157,Unspecified,,,,,"Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Pathology; Tissue: Kidney; Assay: Renal Tubule, Regeneration; Study_ID: 209/7",Other,,
948,782673,1,2,,103188875,2157,Unspecified,,,,,"Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Pathology; Tissue: Kidney; Assay: Renal Tubule, Dilatation, Cystic; Study_ID: 209/8",Other,,
949,782674,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Pathology; Tissue: Liver; Assay: Cellular Infiltration; Study_ID: 209/8,Other,,
950,782675,1,2,,103188875,2157,Unspecified,,,,,"Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Pathology; Tissue: Kidney; Assay: Renal Tubule, Dilatation, Cystic; Study_ID: 209/9",Other,,
951,782676,1,2,,103188875,2157,Unspecified,,,,,"Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Pathology; Tissue: Kidney; Assay: Renal Tubule, Dilatation, Cystic; Study_ID: 209/10",Other,,
952,782677,1,2,,103188875,2157,Unspecified,,,,,"Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Pathology; Tissue: Kidney; Assay: Renal Tubule, Regeneration; Study_ID: 209/11",Other,,
953,782678,1,2,,103188875,2157,Unspecified,,,,,"Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Pathology; Tissue: Liver; Assay: Nodule, Hepatodiaphragmatic; Study_ID: 209/12",Other,,
954,782679,1,2,,103188875,2157,Unspecified,,,,,"Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Pathology; Tissue: Liver; Assay: Portal, Cellular Infiltration; Study_ID: 209/13",Other,,
955,782680,1,2,,103188875,2157,Unspecified,,,,,"Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Pathology; Tissue: Kidney; Assay: Renal Tubule, Regeneration; Study_ID: 209/13",Other,,
956,782681,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Pathology; Tissue: Liver; Assay: Cellular Infiltration; Study_ID: 209/13,Other,,
957,782682,1,2,,103188875,2157,Unspecified,,,,,"Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Pathology; Tissue: Kidney; Assay: Renal Tubule, Dilatation, Cystic; Study_ID: 209/14",Other,,
958,782683,1,2,,103188875,2157,Unspecified,,,,,"Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Pathology; Tissue: Kidney; Assay: Renal Tubule, Vacuolization (Vacuolation), Cytoplasmic; Study_ID: 209/14",Other,,
959,782684,1,2,,103188875,2157,Unspecified,,,,,"Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Cell, Vacuolization, Cytoplasmic; Study_ID: 209/14",Other,,
960,782685,1,2,,103188875,2157,Unspecified,,,,,"Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Pathology; Tissue: Kidney; Assay: Renal Tubule, Regeneration; Study_ID: 209/14",Other,,
961,782686,1,2,,103188875,2157,Unspecified,,,,,"Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Change, Eosinophilic; Study_ID: 209/15",Other,,
962,782687,1,2,,103188875,2157,Unspecified,,,,,"Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Cell, Vacuolization, Cytoplasmic; Study_ID: 209/15",Other,,
963,782688,1,2,,103188875,2157,Unspecified,,,,,"Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Vacuolization, Cytoplasmic; Study_ID: 209/15",Other,,
964,782689,1,2,,103188875,2157,Unspecified,,,,,"Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Pathology; Tissue: Liver; Assay: Kupffer Cell, Vacuolization, Cytoplasmic; Study_ID: 209/15",Other,,
965,782690,1,2,,103188875,2157,Unspecified,,,,,"Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Pathology; Tissue: Kidney; Assay: Renal Tubule, Vacuolization (Vacuolation), Cytoplasmic; Study_ID: 209/15",Other,,
966,782691,1,2,,103188875,2157,Unspecified,,,,,"Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Pathology; Tissue: Kidney; Assay: Renal Tubule, Dilatation, Cystic; Study_ID: 209/15",Other,,
967,782692,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Pathology; Tissue: Kidney; Assay: Nephroblastoma; Study_ID: 209/15,Other,,
968,782693,1,2,,103188875,2157,Unspecified,,,,,"Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Pathology; Tissue: Kidney; Assay: Podocyte, Vacuolization (Vacuolation), Cytoplasmic; Study_ID: 209/15",Other,,
969,782694,1,2,,103188875,2157,Unspecified,,,,,"Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Pathology; Tissue: Liver; Assay: Dead, Dead; Study_ID: 209/16",Other,,
970,782695,1,2,,103188875,2157,Unspecified,,,,,"Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Pathology; Tissue: Kidney; Assay: Dead, Dead; Study_ID: 209/16",Other,,
971,782696,1,2,,103188875,2157,Unspecified,,,,,"Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Pathology; Tissue: Liver; Assay: Centrilobular, Change, Eosinophilic; Study_ID: 209/16",Other,,
972,782697,1,2,,103188875,2157,Unspecified,,,,,"Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Pathology; Tissue: Liver; Assay: Bile Duct Cell, Vacuolization, Cytoplasmic; Study_ID: 209/16",Other,,
973,782698,1,2,,103188875,2157,Unspecified,,,,,"Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Pathology; Tissue: Liver; Assay: Hepatocyte, Vacuolization, Cytoplasmic; Study_ID: 209/16",Other,,
974,782699,1,2,,103188875,2157,Unspecified,,,,,"Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Pathology; Tissue: Liver; Assay: Kupffer Cell, Vacuolization, Cytoplasmic; Study_ID: 209/16",Other,,
975,782700,1,2,,103188875,2157,Unspecified,,,,,"Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Pathology; Tissue: Kidney; Assay: Podocyte, Vacuolization (Vacuolation), Cytoplasmic; Study_ID: 209/16",Other,,
976,782701,1,2,,103188875,2157,Unspecified,,,,,"Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Pathology; Tissue: Kidney; Assay: Renal Tubule, Vacuolization (Vacuolation), Cytoplasmic; Study_ID: 209/16",Other,,
977,782702,1,2,,103188875,2157,Unspecified,,,,,"Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Pathology; Tissue: Kidney; Assay: Renal Tubule, Dilatation, Cystic; Study_ID: 209/16",Other,,
978,782703,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Pathology; Tissue: Liver; Assay: Necrosis; Study_ID: 634/5,Other,,
979,782704,1,2,,103188875,2157,Unspecified,,,,,"Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Pathology; Tissue: Kidney; Assay: Renal Tubule, Dilatation, Cystic; Study_ID: 634/8",Other,,
980,782993,1,2,,103188875,2157,Unspecified,,,,,"Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Pathology; Tissue: Kidney; Assay: Renal Tubule, Dilatation, Cystic; Study_ID: 634/11",Other,,
981,782994,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Pathology; Tissue: Kidney; Assay: Nephroblastoma; Study_ID: 634/11,Other,,
982,782995,1,2,,103188875,2157,Unspecified,,,,,"Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Pathology; Tissue: Kidney; Assay: Renal Tubule, Dilatation, Cystic; Study_ID: 634/13",Other,,
983,782996,1,2,,103188875,2157,Unspecified,,,,,"Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Pathology; Tissue: Liver; Assay: Nodule, Hepatodiaphragmatic; Study_ID: 634/14",Other,,
984,782997,1,2,,103188875,2157,Unspecified,,,,,"Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Pathology; Tissue: Kidney; Assay: Renal Tubule, Dilatation, Cystic; Study_ID: 634/14",Other,,
985,782998,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Pathology; Tissue: Liver; Assay: Necrosis; Study_ID: 634/16,Other,,
986,782999,1,2,,103188875,2157,Unspecified,,,,,"Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Pathology; Tissue: Kidney; Assay: Renal Tubule, Dilatation, Cystic; Study_ID: 634/16",Other,,
987,836528,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 209/5,Other,,
988,836529,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 209/5,Other,,
989,836530,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 209/5,Other,,
990,836531,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 209/5,Other,,
991,836532,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 209/5,Other,,
992,836533,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 209/5,Other,,
993,836534,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 209/5,Other,,
994,836535,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 209/5,Other,,
995,836536,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 209/5,Other,,
996,836537,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 209/5,Other,,
997,836538,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 209/5,Other,,
998,836539,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 209/5,Other,,
999,836540,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 209/5,Other,,
1000,836541,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 209/5,Other,,
1001,836542,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 209/5,Other,,
1002,836543,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 209/5,Other,,
1003,836544,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 209/5,Other,,
1004,836545,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 209/6,Other,,
1005,836546,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 209/6,Other,,
1006,836547,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 209/6,Other,,
1007,836548,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 209/6,Other,,
1008,837125,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 634/5,Other,,
1009,837126,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 634/5,Other,,
1010,837127,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 634/5,Other,,
1011,837128,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 634/5,Other,,
1012,837129,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 634/5,Other,,
1013,837130,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 634/5,Other,,
1014,837131,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 634/5,Other,,
1015,837132,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 634/5,Other,,
1016,837133,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 634/5,Other,,
1017,837134,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 634/5,Other,,
1018,837135,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 634/5,Other,,
1019,837136,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 634/5,Other,,
1020,837137,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 634/5,Other,,
1021,837138,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 634/5,Other,,
1022,837139,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 634/6,Other,,
1023,837140,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 634/6,Other,,
1024,837141,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 634/6,Other,,
1025,837142,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 634/6,Other,,
1026,837143,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 634/6,Other,,
1027,837144,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 634/6,Other,,
1028,837145,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 634/6,Other,,
1029,837146,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 634/6,Other,,
1030,837147,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 634/6,Other,,
1031,837148,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 634/6,Other,,
1032,837149,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 634/6,Other,,
1033,837150,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 634/6,Other,,
1034,837151,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 634/6,Other,,
1035,837826,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 634/6,Other,,
1036,837827,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 634/6,Other,,
1037,837828,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 634/6,Other,,
1038,837829,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 634/6,Other,,
1039,837830,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 634/7,Other,,
1040,837831,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 634/7,Other,,
1041,837832,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 634/7,Other,,
1042,837833,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 634/7,Other,,
1043,837834,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 634/7,Other,,
1044,837835,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 634/7,Other,,
1045,837836,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 634/7,Other,,
1046,837837,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 634/7,Other,,
1047,837838,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 634/7,Other,,
1048,837839,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 634/7,Other,,
1049,837840,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 634/7,Other,,
1050,837841,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 634/7,Other,,
1051,837842,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 634/7,Other,,
1052,837843,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 634/7,Other,,
1053,837844,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 634/7,Other,,
1054,837845,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 634/7,Other,,
1055,837846,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 634/7,Other,,
1056,837881,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 634/16,Other,,
1057,837882,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 634/16,Other,,
1058,837883,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 634/16,Other,,
1059,837884,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 634/16,Other,,
1060,837885,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 634/16,Other,,
1061,837886,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 634/16,Other,,
1062,837887,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 634/16,Other,,
1063,837888,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 634/16,Other,,
1064,837889,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 634/16,Other,,
1065,837890,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 634/16,Other,,
1066,838717,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 209/6,Other,,
1067,838718,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 209/6,Other,,
1068,838719,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 209/6,Other,,
1069,838720,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 209/6,Other,,
1070,838721,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 209/6,Other,,
1071,838722,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 209/6,Other,,
1072,838723,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 209/6,Other,,
1073,838724,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 209/6,Other,,
1074,838725,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 209/6,Other,,
1075,838726,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 209/6,Other,,
1076,839399,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 209/6,Other,,
1077,839400,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 209/6,Other,,
1078,839401,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 209/6,Other,,
1079,839402,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 209/7,Other,,
1080,839403,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 209/7,Other,,
1081,839404,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 209/7,Other,,
1082,839405,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 209/7,Other,,
1083,839406,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 209/7,Other,,
1084,839407,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 209/7,Other,,
1085,839408,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 209/7,Other,,
1086,839409,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 209/7,Other,,
1087,839410,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 209/7,Other,,
1088,839411,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 209/7,Other,,
1089,839412,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 209/7,Other,,
1090,839413,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 209/7,Other,,
1091,839414,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 209/7,Other,,
1092,839415,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 209/7,Other,,
1093,839416,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 209/7,Other,,
1094,839417,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 209/7,Other,,
1095,839418,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 209/7,Other,,
1096,839419,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 209/8,Other,,
1097,839420,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 209/8,Other,,
1098,839421,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 209/8,Other,,
1099,839422,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 209/8,Other,,
1100,839423,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 209/8,Other,,
1101,839424,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 209/8,Other,,
1102,839425,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 209/8,Other,,
1103,839426,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 209/8,Other,,
1104,839427,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 209/8,Other,,
1105,839428,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 209/8,Other,,
1106,839429,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 209/8,Other,,
1107,839430,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 209/8,Other,,
1108,839431,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 209/8,Other,,
1109,839432,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 209/8,Other,,
1110,839433,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 209/8,Other,,
1111,839434,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 209/8,Other,,
1112,839435,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 209/8,Other,,
1113,840007,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 634/8,Other,,
1114,840008,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 634/8,Other,,
1115,840009,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 634/8,Other,,
1116,840010,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 634/8,Other,,
1117,840011,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 634/8,Other,,
1118,840012,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 634/8,Other,,
1119,840013,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 634/8,Other,,
1120,840014,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 634/8,Other,,
1121,840015,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 634/8,Other,,
1122,840016,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 634/8,Other,,
1123,840017,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 634/8,Other,,
1124,840018,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 634/8,Other,,
1125,840019,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 634/8,Other,,
1126,840020,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 634/8,Other,,
1127,840021,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 634/8,Other,,
1128,840022,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 634/8,Other,,
1129,840023,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 634/8,Other,,
1130,840024,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 634/9,Other,,
1131,840025,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 634/9,Other,,
1132,840697,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 634/9,Other,,
1133,840698,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 634/9,Other,,
1134,840699,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 634/9,Other,,
1135,840700,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 634/9,Other,,
1136,840701,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 634/9,Other,,
1137,840702,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 634/9,Other,,
1138,840703,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 634/9,Other,,
1139,840704,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 634/9,Other,,
1140,840705,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 634/9,Other,,
1141,840706,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 634/9,Other,,
1142,840707,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 634/9,Other,,
1143,840708,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 634/9,Other,,
1144,840709,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 634/9,Other,,
1145,840710,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 634/9,Other,,
1146,840711,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 634/9,Other,,
1147,840712,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 634/10,Other,,
1148,840713,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 634/10,Other,,
1149,840714,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 634/10,Other,,
1150,840715,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 634/10,Other,,
1151,840716,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 634/10,Other,,
1152,840717,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 634/10,Other,,
1153,840718,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 634/10,Other,,
1154,840719,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 634/10,Other,,
1155,840720,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 634/10,Other,,
1156,840721,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 634/10,Other,,
1157,840722,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 634/10,Other,,
1158,840723,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 634/10,Other,,
1159,840724,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 634/10,Other,,
1160,840725,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 634/10,Other,,
1161,842268,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 209/9,Other,,
1162,842269,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 209/9,Other,,
1163,842270,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 209/9,Other,,
1164,842271,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 209/9,Other,,
1165,842272,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 209/9,Other,,
1166,842273,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 209/9,Other,,
1167,842274,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 209/9,Other,,
1168,842275,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 209/9,Other,,
1169,842276,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 209/9,Other,,
1170,842277,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 209/9,Other,,
1171,842278,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 209/9,Other,,
1172,842279,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 209/9,Other,,
1173,842280,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 209/9,Other,,
1174,842281,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 209/9,Other,,
1175,842282,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 209/9,Other,,
1176,842283,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 209/9,Other,,
1177,842284,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 209/9,Other,,
1178,842285,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 209/10,Other,,
1179,842286,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 209/10,Other,,
1180,842287,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 209/10,Other,,
1181,842288,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 209/10,Other,,
1182,842289,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 209/10,Other,,
1183,842290,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 209/10,Other,,
1184,842291,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 209/10,Other,,
1185,842292,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 209/10,Other,,
1186,842293,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 209/10,Other,,
1187,842294,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 209/10,Other,,
1188,842295,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 209/10,Other,,
1189,842296,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 209/10,Other,,
1190,842297,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 209/10,Other,,
1191,842298,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 209/10,Other,,
1192,842299,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 209/10,Other,,
1193,842300,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 209/10,Other,,
1194,842301,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 209/10,Other,,
1195,842302,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 209/11,Other,,
1196,842303,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 209/11,Other,,
1197,842304,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 209/11,Other,,
1198,842305,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 209/11,Other,,
1199,842306,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 209/11,Other,,
1200,842307,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 209/11,Other,,
1201,842308,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 209/11,Other,,
1202,842309,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 209/11,Other,,
1203,842310,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 209/11,Other,,
1204,842311,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 209/11,Other,,
1205,842889,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 634/10,Other,,
1206,842890,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 634/10,Other,,
1207,842891,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 634/10,Other,,
1208,842892,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 634/11,Other,,
1209,842893,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 634/11,Other,,
1210,842894,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 634/11,Other,,
1211,842895,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 634/11,Other,,
1212,842896,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 634/11,Other,,
1213,842897,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 634/11,Other,,
1214,842989,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 209/11,Other,,
1215,842990,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 209/11,Other,,
1216,843571,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 634/11,Other,,
1217,843572,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 634/11,Other,,
1218,843573,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 634/11,Other,,
1219,843574,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 634/11,Other,,
1220,843575,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 634/11,Other,,
1221,843576,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 634/11,Other,,
1222,843577,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 634/11,Other,,
1223,843578,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 634/11,Other,,
1224,843579,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 634/11,Other,,
1225,843580,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 634/11,Other,,
1226,843581,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 634/11,Other,,
1227,843582,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 634/12,Other,,
1228,843583,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 634/12,Other,,
1229,843584,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 634/12,Other,,
1230,843585,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 634/12,Other,,
1231,843586,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 634/12,Other,,
1232,843587,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 634/12,Other,,
1233,843588,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 634/12,Other,,
1234,843589,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 634/12,Other,,
1235,843590,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 634/12,Other,,
1236,843591,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 634/12,Other,,
1237,843592,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 634/12,Other,,
1238,843593,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 634/12,Other,,
1239,843594,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 634/12,Other,,
1240,843595,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 634/12,Other,,
1241,843596,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 634/12,Other,,
1242,843597,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 634/12,Other,,
1243,843598,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 634/12,Other,,
1244,843599,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 634/13,Other,,
1245,843600,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 634/13,Other,,
1246,843601,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 634/13,Other,,
1247,843602,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 634/13,Other,,
1248,843603,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 634/13,Other,,
1249,843604,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 634/13,Other,,
1250,843605,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 634/13,Other,,
1251,843606,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 634/13,Other,,
1252,843607,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 634/13,Other,,
1253,843608,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 634/13,Other,,
1254,845148,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 209/11,Other,,
1255,845149,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 209/11,Other,,
1256,845150,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 209/11,Other,,
1257,845151,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 209/11,Other,,
1258,845152,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 209/11,Other,,
1259,845153,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 209/12,Other,,
1260,845154,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 209/12,Other,,
1261,845155,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 209/12,Other,,
1262,845156,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 209/12,Other,,
1263,845157,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 209/12,Other,,
1264,845158,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 209/12,Other,,
1265,845159,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 209/12,Other,,
1266,845160,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 209/12,Other,,
1267,845161,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 209/12,Other,,
1268,845162,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 209/12,Other,,
1269,845163,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 209/12,Other,,
1270,845164,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 209/12,Other,,
1271,845165,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 209/12,Other,,
1272,845166,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 209/12,Other,,
1273,845167,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 209/12,Other,,
1274,845168,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 209/12,Other,,
1275,845169,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 209/12,Other,,
1276,845170,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 209/13,Other,,
1277,845171,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 209/13,Other,,
1278,845172,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 209/13,Other,,
1279,845173,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 209/13,Other,,
1280,845174,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 209/13,Other,,
1281,845175,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 209/13,Other,,
1282,845176,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 209/13,Other,,
1283,845177,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 209/13,Other,,
1284,845178,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 209/13,Other,,
1285,845179,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 209/13,Other,,
1286,845180,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 209/13,Other,,
1287,845181,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 209/13,Other,,
1288,845182,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 209/13,Other,,
1289,845183,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 209/13,Other,,
1290,845688,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 209/14,Other,,
1291,845689,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 209/14,Other,,
1292,845690,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 209/14,Other,,
1293,845691,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 209/14,Other,,
1294,845692,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 209/14,Other,,
1295,845693,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 209/14,Other,,
1296,845694,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 209/14,Other,,
1297,845695,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 209/14,Other,,
1298,845696,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 209/14,Other,,
1299,845697,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 209/14,Other,,
1300,845698,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 209/15,Other,,
1301,845699,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 209/15,Other,,
1302,845700,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 209/15,Other,,
1303,845701,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 209/15,Other,,
1304,845702,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 209/15,Other,,
1305,845703,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 209/15,Other,,
1306,845704,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 209/15,Other,,
1307,845705,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 209/15,Other,,
1308,845706,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 209/15,Other,,
1309,845707,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 209/15,Other,,
1310,845708,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 209/15,Other,,
1311,845709,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 209/15,Other,,
1312,845710,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 209/15,Other,,
1313,845711,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 209/15,Other,,
1314,845712,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 209/15,Other,,
1315,845713,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 209/15,Other,,
1316,845714,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 209/15,Other,,
1317,845715,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 209/16,Other,,
1318,845716,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 209/16,Other,,
1319,845717,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 209/16,Other,,
1320,845718,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 209/16,Other,,
1321,845719,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 209/16,Other,,
1322,845720,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 209/16,Other,,
1323,845721,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 209/16,Other,,
1324,845767,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 634/13,Other,,
1325,845857,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 209/13,Other,,
1326,845858,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 209/13,Other,,
1327,845859,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 209/13,Other,,
1328,845860,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 209/14,Other,,
1329,845861,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 209/14,Other,,
1330,845862,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 209/14,Other,,
1331,845863,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 209/14,Other,,
1332,845864,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 209/14,Other,,
1333,845865,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 209/14,Other,,
1334,845866,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 209/14,Other,,
1335,846392,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 209/16,Other,,
1336,846393,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 209/16,Other,,
1337,846394,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 209/16,Other,,
1338,846395,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 209/16,Other,,
1339,846396,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 209/16,Other,,
1340,846397,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 209/16,Other,,
1341,846398,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 209/16,Other,,
1342,846399,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 209/16,Other,,
1343,846400,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 209/16,Other,,
1344,846401,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 209/16,Other,,
1345,846402,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 634/5,Other,,
1346,846403,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 634/5,Other,,
1347,846404,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 634/5,Other,,
1348,846436,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 634/13,Other,,
1349,846437,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 634/13,Other,,
1350,846438,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 634/13,Other,,
1351,846439,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 634/13,Other,,
1352,846440,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 634/13,Other,,
1353,846441,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 634/13,Other,,
1354,846442,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 634/14,Other,,
1355,846443,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 634/14,Other,,
1356,846444,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 634/14,Other,,
1357,846445,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 634/14,Other,,
1358,846446,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 634/14,Other,,
1359,846447,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 634/14,Other,,
1360,846448,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 634/14,Other,,
1361,846449,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 634/14,Other,,
1362,846450,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 634/14,Other,,
1363,846451,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 634/14,Other,,
1364,846452,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 634/14,Other,,
1365,846453,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 634/14,Other,,
1366,846454,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 634/14,Other,,
1367,846455,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 634/14,Other,,
1368,846456,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 634/14,Other,,
1369,846457,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 634/14,Other,,
1370,846458,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 634/14,Other,,
1371,846459,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 634/15,Other,,
1372,846460,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 634/15,Other,,
1373,846461,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 634/15,Other,,
1374,846462,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 634/15,Other,,
1375,846463,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 634/15,Other,,
1376,846464,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 634/15,Other,,
1377,846465,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 634/15,Other,,
1378,846466,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: 634/15,Other,,
1379,846467,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: 634/15,Other,,
1380,846468,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: 634/15,Other,,
1381,846469,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: 634/15,Other,,
1382,846470,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: 634/15,Other,,
1383,846471,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: 634/15,Other,,
1384,846472,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: 634/15,Other,,
1385,846473,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: PT (Prothrombin Time); Study_ID: 634/15,Other,,
1386,846474,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: APTT (Activated Partial Thromboplastin Time); Study_ID: 634/15,Other,,
1387,846475,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: FIBRINO (Fibrinogen); Study_ID: 634/15,Other,,
1388,846476,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: 634/16,Other,,
1389,846477,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: 634/16,Other,,
1390,846478,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: 634/16,Other,,
1391,846479,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: 634/16,Other,,
1392,846480,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: 634/16,Other,,
1393,847153,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: 634/16,Other,,
1394,847154,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Hematology; Assay: RETIRBC (Reticulocytes/Erythrocytes); Study_ID: 634/16,Other,,
1395,860568,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 209/9,Other,,
1396,860569,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 209/9,Other,,
1397,860570,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 209/9,Other,,
1398,860571,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 209/9,Other,,
1399,860572,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 209/9,Other,,
1400,860573,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 209/9,Other,,
1401,860574,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 209/9,Other,,
1402,860575,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 209/9,Other,,
1403,860576,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 209/9,Other,,
1404,860577,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 209/9,Other,,
1405,860578,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 209/9,Other,,
1406,860579,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 209/9,Other,,
1407,860580,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 209/9,Other,,
1408,860581,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 209/9,Other,,
1409,860582,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 209/9,Other,,
1410,860583,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 209/9,Other,,
1411,860584,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 209/10,Other,,
1412,860813,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 634/13,Other,,
1413,860814,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 634/13,Other,,
1414,860815,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 634/13,Other,,
1415,860816,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 634/13,Other,,
1416,860817,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 634/13,Other,,
1417,860818,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 634/13,Other,,
1418,860819,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 634/13,Other,,
1419,860820,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 634/13,Other,,
1420,860821,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 634/13,Other,,
1421,860822,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 634/13,Other,,
1422,860823,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 634/13,Other,,
1423,860824,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 634/14,Other,,
1424,860825,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 634/14,Other,,
1425,860826,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 634/14,Other,,
1426,860827,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 634/14,Other,,
1427,860828,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 634/14,Other,,
1428,860829,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 634/14,Other,,
1429,860830,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 634/14,Other,,
1430,860831,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 634/14,Other,,
1431,860832,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 634/14,Other,,
1432,860833,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 634/14,Other,,
1433,860834,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 634/14,Other,,
1434,860835,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 634/14,Other,,
1435,860836,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 634/14,Other,,
1436,860837,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 634/14,Other,,
1437,860838,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 634/14,Other,,
1438,860839,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 634/14,Other,,
1439,860840,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 634/14,Other,,
1440,860841,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 634/14,Other,,
1441,860842,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 634/14,Other,,
1442,860843,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 634/14,Other,,
1443,860844,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 634/14,Other,,
1444,860845,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 634/15,Other,,
1445,860846,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 634/15,Other,,
1446,860847,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 634/15,Other,,
1447,860848,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 634/15,Other,,
1448,860849,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 634/15,Other,,
1449,860850,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 634/15,Other,,
1450,860851,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 634/15,Other,,
1451,860852,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 634/15,Other,,
1452,861269,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 209/10,Other,,
1453,861270,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 209/10,Other,,
1454,861271,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 209/10,Other,,
1455,861272,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 209/10,Other,,
1456,861273,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 209/10,Other,,
1457,861274,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 209/10,Other,,
1458,861275,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 209/10,Other,,
1459,861276,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 209/10,Other,,
1460,861277,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 209/10,Other,,
1461,861278,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 209/10,Other,,
1462,861279,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 209/10,Other,,
1463,861280,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 209/10,Other,,
1464,861281,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 209/10,Other,,
1465,861282,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 209/10,Other,,
1466,861283,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 209/10,Other,,
1467,861284,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 209/10,Other,,
1468,861285,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 209/10,Other,,
1469,861286,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 209/10,Other,,
1470,861287,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 209/10,Other,,
1471,861288,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 209/10,Other,,
1472,861289,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 209/11,Other,,
1473,861290,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 209/11,Other,,
1474,861291,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 209/11,Other,,
1475,861292,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 209/11,Other,,
1476,861293,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 209/11,Other,,
1477,861294,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 209/11,Other,,
1478,861295,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 209/11,Other,,
1479,861296,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 209/11,Other,,
1480,861297,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 209/11,Other,,
1481,861298,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 209/11,Other,,
1482,862091,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 634/15,Other,,
1483,862092,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 634/15,Other,,
1484,862093,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 634/15,Other,,
1485,862094,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 634/15,Other,,
1486,862095,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 634/15,Other,,
1487,862096,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 634/15,Other,,
1488,862097,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 634/15,Other,,
1489,862098,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 634/15,Other,,
1490,862099,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 634/15,Other,,
1491,862100,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 634/15,Other,,
1492,862101,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 634/15,Other,,
1493,862102,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 634/15,Other,,
1494,862103,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 634/15,Other,,
1495,862104,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 634/16,Other,,
1496,862105,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 634/16,Other,,
1497,862106,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 634/16,Other,,
1498,862107,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 634/16,Other,,
1499,862108,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 634/16,Other,,
1500,862109,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 634/16,Other,,
1501,862110,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 634/16,Other,,
1502,862111,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 634/16,Other,,
1503,862112,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 634/16,Other,,
1504,862113,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 634/16,Other,,
1505,862114,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 634/16,Other,,
1506,862115,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 634/16,Other,,
1507,862116,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 634/16,Other,,
1508,862117,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 634/16,Other,,
1509,862118,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 634/16,Other,,
1510,862119,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 634/16,Other,,
1511,862120,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 634/16,Other,,
1512,862121,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 634/16,Other,,
1513,862122,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 634/16,Other,,
1514,862123,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 634/16,Other,,
1515,862124,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 634/16,Other,,
1516,862962,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 634/6,Other,,
1517,862963,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 634/6,Other,,
1518,862964,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 634/6,Other,,
1519,862965,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 634/6,Other,,
1520,862966,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 634/6,Other,,
1521,862967,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 634/6,Other,,
1522,862968,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 634/6,Other,,
1523,862969,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 634/6,Other,,
1524,862970,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 634/6,Other,,
1525,862971,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 634/6,Other,,
1526,862972,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 634/6,Other,,
1527,862973,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 634/6,Other,,
1528,862974,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 634/6,Other,,
1529,862975,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 634/6,Other,,
1530,862976,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 634/6,Other,,
1531,862977,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 634/6,Other,,
1532,862978,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 634/7,Other,,
1533,862979,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 634/7,Other,,
1534,862980,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 634/7,Other,,
1535,862981,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 634/7,Other,,
1536,862982,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 634/7,Other,,
1537,862983,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 634/7,Other,,
1538,862984,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 634/7,Other,,
1539,862985,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 634/7,Other,,
1540,862986,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 634/7,Other,,
1541,862987,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 634/7,Other,,
1542,862988,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 634/7,Other,,
1543,862989,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 634/7,Other,,
1544,862990,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 634/7,Other,,
1545,862991,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 634/7,Other,,
1546,862992,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 634/7,Other,,
1547,862993,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 634/7,Other,,
1548,862994,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 634/7,Other,,
1549,862995,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 634/7,Other,,
1550,863486,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 209/11,Other,,
1551,863487,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 209/11,Other,,
1552,863488,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 209/11,Other,,
1553,863489,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 209/11,Other,,
1554,863490,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 209/11,Other,,
1555,863491,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 209/11,Other,,
1556,863492,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 209/11,Other,,
1557,863493,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 209/11,Other,,
1558,863674,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 634/7,Other,,
1559,863675,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 634/7,Other,,
1560,863676,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 634/7,Other,,
1561,863677,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 634/8,Other,,
1562,863678,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 634/8,Other,,
1563,863679,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 634/8,Other,,
1564,863680,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 634/8,Other,,
1565,863681,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 634/8,Other,,
1566,863682,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 634/8,Other,,
1567,863683,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 634/8,Other,,
1568,863684,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 634/8,Other,,
1569,863685,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 634/8,Other,,
1570,863686,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 634/8,Other,,
1571,863687,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 634/8,Other,,
1572,864172,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 209/11,Other,,
1573,864173,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 209/11,Other,,
1574,864174,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 209/11,Other,,
1575,864175,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 209/12,Other,,
1576,864176,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 209/12,Other,,
1577,864177,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 209/12,Other,,
1578,864178,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 209/12,Other,,
1579,864179,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 209/12,Other,,
1580,864180,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 209/12,Other,,
1581,864181,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 209/12,Other,,
1582,864182,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 209/12,Other,,
1583,864183,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 209/12,Other,,
1584,864184,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 209/12,Other,,
1585,864185,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 209/12,Other,,
1586,864186,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 209/12,Other,,
1587,864187,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 209/12,Other,,
1588,864188,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 209/12,Other,,
1589,864189,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 209/12,Other,,
1590,864190,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 209/12,Other,,
1591,864191,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 209/12,Other,,
1592,864192,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 209/12,Other,,
1593,864193,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 209/12,Other,,
1594,864194,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 209/12,Other,,
1595,864195,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 209/12,Other,,
1596,864196,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 209/13,Other,,
1597,864197,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 209/13,Other,,
1598,864198,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 209/13,Other,,
1599,864199,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 209/13,Other,,
1600,864200,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 209/13,Other,,
1601,864201,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 209/13,Other,,
1602,864202,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 209/13,Other,,
1603,864203,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 209/13,Other,,
1604,864204,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 209/13,Other,,
1605,864205,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 209/13,Other,,
1606,864206,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 209/13,Other,,
1607,864207,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 209/13,Other,,
1608,864208,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 209/13,Other,,
1609,864209,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 209/13,Other,,
1610,864210,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 209/13,Other,,
1611,865874,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 634/8,Other,,
1612,865875,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 634/8,Other,,
1613,865876,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 634/8,Other,,
1614,865877,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 634/8,Other,,
1615,865878,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 634/8,Other,,
1616,865879,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 634/8,Other,,
1617,865880,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 634/8,Other,,
1618,865881,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 634/8,Other,,
1619,865882,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 634/8,Other,,
1620,865883,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 634/8,Other,,
1621,865884,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 634/9,Other,,
1622,865885,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 634/9,Other,,
1623,865886,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 634/9,Other,,
1624,865887,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 634/9,Other,,
1625,865888,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 634/9,Other,,
1626,865889,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 634/9,Other,,
1627,865890,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 634/9,Other,,
1628,865891,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 634/9,Other,,
1629,865892,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 634/9,Other,,
1630,865893,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 634/9,Other,,
1631,865894,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 634/9,Other,,
1632,865895,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 634/9,Other,,
1633,865896,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 634/9,Other,,
1634,865897,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 634/9,Other,,
1635,865898,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 634/9,Other,,
1636,865899,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 634/9,Other,,
1637,866324,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 209/5,Other,,
1638,866325,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 209/5,Other,,
1639,866326,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 209/5,Other,,
1640,866327,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 209/5,Other,,
1641,866328,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 209/5,Other,,
1642,866329,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 209/5,Other,,
1643,866330,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 209/5,Other,,
1644,866331,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 209/5,Other,,
1645,866332,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 209/5,Other,,
1646,866333,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 209/5,Other,,
1647,866334,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 209/5,Other,,
1648,866335,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 209/5,Other,,
1649,866336,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 209/5,Other,,
1650,866337,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 209/5,Other,,
1651,866338,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 209/5,Other,,
1652,866339,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 209/5,Other,,
1653,866340,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 209/5,Other,,
1654,866341,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 209/5,Other,,
1655,866342,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 209/5,Other,,
1656,866343,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 209/5,Other,,
1657,866344,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 209/5,Other,,
1658,866345,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 209/6,Other,,
1659,866346,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 209/6,Other,,
1660,866347,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 209/6,Other,,
1661,866348,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 209/6,Other,,
1662,866349,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 209/6,Other,,
1663,866350,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 209/6,Other,,
1664,866351,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 209/6,Other,,
1665,866352,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 209/6,Other,,
1666,866579,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 634/9,Other,,
1667,866580,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 634/9,Other,,
1668,866581,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 634/9,Other,,
1669,866582,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 634/9,Other,,
1670,866583,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 634/9,Other,,
1671,866584,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 634/10,Other,,
1672,866585,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 634/10,Other,,
1673,866586,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 634/10,Other,,
1674,866587,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 634/10,Other,,
1675,866588,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 634/10,Other,,
1676,866589,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 634/10,Other,,
1677,866590,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 634/10,Other,,
1678,866591,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 634/10,Other,,
1679,866592,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 634/10,Other,,
1680,866593,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 634/10,Other,,
1681,866594,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 634/10,Other,,
1682,866595,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 634/10,Other,,
1683,866596,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 634/10,Other,,
1684,866597,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 634/10,Other,,
1685,866598,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 634/10,Other,,
1686,866599,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 634/10,Other,,
1687,866600,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 634/10,Other,,
1688,867031,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 209/6,Other,,
1689,867032,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 209/6,Other,,
1690,867033,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 209/6,Other,,
1691,867034,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 209/6,Other,,
1692,867035,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 209/6,Other,,
1693,867036,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 209/6,Other,,
1694,867037,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 209/6,Other,,
1695,867038,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 209/6,Other,,
1696,867039,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 209/6,Other,,
1697,867040,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 209/6,Other,,
1698,867041,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 209/6,Other,,
1699,867042,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 209/6,Other,,
1700,867043,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 209/6,Other,,
1701,867076,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 209/13,Other,,
1702,867077,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 209/13,Other,,
1703,867078,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 209/13,Other,,
1704,867079,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 209/13,Other,,
1705,867080,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 209/13,Other,,
1706,867081,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 209/13,Other,,
1707,867082,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 209/14,Other,,
1708,867083,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 209/14,Other,,
1709,867084,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 209/14,Other,,
1710,867085,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 209/14,Other,,
1711,867086,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 209/14,Other,,
1712,867087,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 209/14,Other,,
1713,867088,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 209/14,Other,,
1714,867089,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 209/14,Other,,
1715,867090,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 209/14,Other,,
1716,867091,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 209/14,Other,,
1717,867092,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 209/14,Other,,
1718,867093,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 209/14,Other,,
1719,867094,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 209/14,Other,,
1720,867095,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 209/14,Other,,
1721,867096,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 209/14,Other,,
1722,867097,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 209/14,Other,,
1723,867098,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 209/14,Other,,
1724,867099,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 209/14,Other,,
1725,867100,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 209/14,Other,,
1726,867101,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 209/14,Other,,
1727,867102,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 209/14,Other,,
1728,867103,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 209/15,Other,,
1729,867104,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 209/15,Other,,
1730,867105,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 209/15,Other,,
1731,867106,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 209/15,Other,,
1732,867107,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 209/15,Other,,
1733,867108,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 209/15,Other,,
1734,867109,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 209/15,Other,,
1735,867110,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 209/15,Other,,
1736,867111,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 209/15,Other,,
1737,867112,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 209/15,Other,,
1738,867113,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 209/15,Other,,
1739,867114,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 209/15,Other,,
1740,867115,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 209/15,Other,,
1741,867116,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 209/15,Other,,
1742,867117,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 209/15,Other,,
1743,867118,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 209/15,Other,,
1744,867119,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 209/15,Other,,
1745,867120,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 209/15,Other,,
1746,867802,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 209/15,Other,,
1747,867803,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 209/15,Other,,
1748,868783,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 634/10,Other,,
1749,868784,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 634/10,Other,,
1750,868785,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 634/10,Other,,
1751,868786,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 634/10,Other,,
1752,868787,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 634/11,Other,,
1753,868788,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 634/11,Other,,
1754,868789,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 634/11,Other,,
1755,868790,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 634/11,Other,,
1756,868791,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 634/11,Other,,
1757,868792,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 634/11,Other,,
1758,868793,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 634/11,Other,,
1759,868794,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 634/11,Other,,
1760,868795,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 634/11,Other,,
1761,868796,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 634/11,Other,,
1762,868797,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 634/11,Other,,
1763,868798,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 634/11,Other,,
1764,868799,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 634/11,Other,,
1765,869226,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 209/7,Other,,
1766,869227,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 209/7,Other,,
1767,869228,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 209/7,Other,,
1768,869229,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 209/7,Other,,
1769,869230,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 209/7,Other,,
1770,869231,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 209/7,Other,,
1771,869232,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 209/7,Other,,
1772,869233,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 209/7,Other,,
1773,869234,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 209/7,Other,,
1774,869235,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 209/7,Other,,
1775,869236,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 209/7,Other,,
1776,869237,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 209/7,Other,,
1777,869238,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 209/7,Other,,
1778,869239,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 209/7,Other,,
1779,869240,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 209/7,Other,,
1780,869241,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 209/7,Other,,
1781,869242,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 209/7,Other,,
1782,869243,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 209/7,Other,,
1783,869244,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 209/7,Other,,
1784,869245,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 209/7,Other,,
1785,869246,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 209/7,Other,,
1786,869247,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 209/8,Other,,
1787,869248,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 209/8,Other,,
1788,869249,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 209/8,Other,,
1789,869250,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 209/8,Other,,
1790,869251,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 209/8,Other,,
1791,869478,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 634/11,Other,,
1792,869479,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 634/11,Other,,
1793,869480,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 634/11,Other,,
1794,869481,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 634/11,Other,,
1795,869482,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 634/11,Other,,
1796,869483,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 634/11,Other,,
1797,869484,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 634/11,Other,,
1798,869485,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 634/11,Other,,
1799,869486,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 634/12,Other,,
1800,869487,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 634/12,Other,,
1801,869488,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 634/12,Other,,
1802,869489,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 634/12,Other,,
1803,869490,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 634/12,Other,,
1804,869491,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 634/12,Other,,
1805,869492,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 634/12,Other,,
1806,869493,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 634/12,Other,,
1807,869494,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 634/12,Other,,
1808,869495,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 634/12,Other,,
1809,869496,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 634/12,Other,,
1810,869497,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 634/12,Other,,
1811,869498,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 634/12,Other,,
1812,869499,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 634/12,Other,,
1813,869500,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 634/12,Other,,
1814,869501,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 634/12,Other,,
1815,869502,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 634/12,Other,,
1816,869503,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 634/12,Other,,
1817,869504,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 634/12,Other,,
1818,869505,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 634/12,Other,,
1819,869506,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 634/12,Other,,
1820,869507,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 634/13,Other,,
1821,869508,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 634/13,Other,,
1822,869931,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 209/8,Other,,
1823,869932,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 209/8,Other,,
1824,869933,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 209/8,Other,,
1825,869934,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 209/8,Other,,
1826,869935,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 209/8,Other,,
1827,869936,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 209/8,Other,,
1828,869937,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 209/8,Other,,
1829,869938,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 209/8,Other,,
1830,869939,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 209/8,Other,,
1831,869940,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 209/8,Other,,
1832,869941,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 209/8,Other,,
1833,869942,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 209/8,Other,,
1834,869943,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 209/8,Other,,
1835,869944,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 209/8,Other,,
1836,869945,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 209/8,Other,,
1837,869946,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 209/8,Other,,
1838,869947,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 209/9,Other,,
1839,869948,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 209/9,Other,,
1840,869949,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 209/9,Other,,
1841,869950,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 209/9,Other,,
1842,869951,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 209/9,Other,,
1843,869985,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 209/15,Other,,
1844,869986,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 209/16,Other,,
1845,869987,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 209/16,Other,,
1846,869988,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 209/16,Other,,
1847,869989,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 209/16,Other,,
1848,869990,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 209/16,Other,,
1849,869991,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 209/16,Other,,
1850,869992,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 209/16,Other,,
1851,869993,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 209/16,Other,,
1852,869994,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 209/16,Other,,
1853,869995,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 209/16,Other,,
1854,869996,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 209/16,Other,,
1855,869997,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 209/16,Other,,
1856,869998,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 209/16,Other,,
1857,869999,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 209/16,Other,,
1858,870000,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 209/16,Other,,
1859,870001,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 209/16,Other,,
1860,870002,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 209/16,Other,,
1861,870003,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 209/16,Other,,
1862,870004,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 209/16,Other,,
1863,870005,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 209/16,Other,,
1864,870006,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 209/16,Other,,
1865,870007,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 634/5,Other,,
1866,870008,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 634/5,Other,,
1867,870009,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 634/5,Other,,
1868,870010,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 634/5,Other,,
1869,870011,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 634/5,Other,,
1870,870012,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 634/5,Other,,
1871,870013,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 634/5,Other,,
1872,870014,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 634/5,Other,,
1873,870015,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 634/5,Other,,
1874,870016,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 634/5,Other,,
1875,870017,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: 634/5,Other,,
1876,870018,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: 634/5,Other,,
1877,870019,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CALCIUM (Calcium); Study_ID: 634/5,Other,,
1878,870020,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: 634/5,Other,,
1879,870700,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: 634/5,Other,,
1880,870701,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: 634/5,Other,,
1881,870702,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALBGLOB (Albumin/Globulin); Study_ID: 634/5,Other,,
1882,870703,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: 634/5,Other,,
1883,870704,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: 634/5,Other,,
1884,870705,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: 634/5,Other,,
1885,870706,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: GGT (Gamma Glutamyl Transferase); Study_ID: 634/5,Other,,
1886,870707,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: 634/6,Other,,
1887,870708,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: 634/6,Other,,
1888,870709,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 634/6,Other,,
1889,870710,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 634/6,Other,,
1890,870711,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 634/6,Other,,
1891,871694,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: TRIG (Triglycerides); Study_ID: 634/13,Other,,
1892,871695,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: PHOSLPD (Phospholipid); Study_ID: 634/13,Other,,
1893,871696,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: 634/13,Other,,
1894,871697,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BILDIR (Direct Bilirubin); Study_ID: 634/13,Other,,
1895,871698,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: 634/13,Other,,
1896,871699,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: 634/13,Other,,
1897,871700,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: 634/13,Other,,
1898,871701,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: 634/13,Other,,
1899,929619,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: R020910,Other,,
1900,929620,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: R020910,Other,,
1901,929621,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: R020910,Other,,
1902,929622,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: R020910,Other,,
1903,929623,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: R020910,Other,,
1904,929624,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: R020910,Other,,
1905,929625,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: R020910,Other,,
1906,929626,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: R020910,Other,,
1907,929627,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: R020910,Other,,
1908,929628,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: R020910,Other,,
1909,929629,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: R020910,Other,,
1910,929630,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: R020910,Other,,
1911,929631,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: R020910,Other,,
1912,946332,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: R020910,Other,,
1913,946333,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: R020910,Other,,
1914,946334,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: R020910,Other,,
1915,946335,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: R020910,Other,,
1916,946336,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: R020910,Other,,
1917,946337,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: R020910,Other,,
1918,946338,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: R020910,Other,,
1919,946339,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: R020910,Other,,
1920,946340,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: R020910,Other,,
1921,946341,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: R020910,Other,,
1922,946342,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: R020910,Other,,
1923,946343,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: R020910,Other,,
1924,946344,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: R020910,Other,,
1925,963990,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: R020910,Other,,
1926,963991,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: R020910,Other,,
1927,963992,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: R020910,Other,,
1928,963993,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: R020910,Other,,
1929,963994,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: R020910,Other,,
1930,963995,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: R020910,Other,,
1931,963996,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: R020910,Other,,
1932,963997,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: R020910,Other,,
1933,963998,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: R020910,Other,,
1934,963999,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: R020910,Other,,
1935,964000,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: R020910,Other,,
1936,964001,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: R020910,Other,,
1937,964002,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: R020910,Other,,
1938,964003,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: R020910,Other,,
1939,964004,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: R020910,Other,,
1940,967306,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: R020910,Other,,
1941,967307,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: R020910,Other,,
1942,967308,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: R020910,Other,,
1943,967309,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: R020910,Other,,
1944,967310,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: R020910,Other,,
1945,967311,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: R020910,Other,,
1946,967312,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: R020910,Other,,
1947,967313,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: R020910,Other,,
1948,967314,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: R020910,Other,,
1949,967315,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: R020910,Other,,
1950,967316,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: R020910,Other,,
1951,977385,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: R020910,Other,,
1952,977386,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: R020910,Other,,
1953,977387,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: R020910,Other,,
1954,977388,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: R020910,Other,,
1955,1009292,1,3,,103188875,2157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Lipid Accumulation; Study_ID: R020910",Other,,
1956,1009293,1,3,,103188875,2157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Inflammation, Chronic; Study_ID: R020910",Other,,
1957,1009294,1,3,,103188875,2157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Mineralization; Study_ID: R020910",Other,,
1958,1009295,1,3,,103188875,2157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Necrosis; Study_ID: R020910",Other,,
1959,1009296,1,3,,103188875,2157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Degeneration; Study_ID: R020910",Other,,
1960,1009297,1,3,,103188875,2157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Edema; Study_ID: R020910",Other,,
1961,1009298,1,3,,103188875,2157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Fibrosis; Study_ID: R020910",Other,,
1962,1009299,1,3,,103188875,2157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mixed Cell; Study_ID: R020910",Other,,
1963,1009300,1,3,,103188875,2157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: R020910",Other,,
1964,1009301,1,3,,103188875,2157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Vacuolation; Study_ID: R020910",Other,,
1965,1009302,1,3,,103188875,2157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Fibrosis; Study_ID: R020910",Other,,
1966,1009303,1,3,,103188875,2157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Mineralization; Study_ID: R020910",Other,,
1967,1009884,1,3,,103188875,2157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Cyst(S); Study_ID: R020910",Other,,
1968,1009885,1,3,,103188875,2157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Hyperplasia; Study_ID: R020910",Other,,
1969,1009886,1,3,,103188875,2157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mononuclear Cell; Study_ID: R020910",Other,,
1970,1009887,1,3,,103188875,2157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Necrosis, Fibrinoid; Study_ID: R020910",Other,,
1971,1009888,1,3,,103188875,2157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Fibrosis; Study_ID: R020910",Other,,
1972,1009889,1,3,,103188875,2157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Dilatation; Study_ID: R020910",Other,,
1973,1009890,1,3,,103188875,2157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: R020910",Other,,
1974,1009891,1,3,,103188875,2157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Myocyte, Degeneration; Study_ID: R020910",Other,,
1975,1009892,1,3,,103188875,2157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Inflammation, Subacute; Study_ID: R020910",Other,,
1976,1009893,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Nephropathy; Study_ID: R020910,Other,,
1977,1009894,1,3,,103188875,2157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Urothelial Hyperplasia; Study_ID: R020910",Other,,
1978,1009895,1,3,,103188875,2157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mononuclear Cell; Study_ID: R020910",Other,,
1979,1009896,1,3,,103188875,2157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mononuclear Cell; Study_ID: R020910",Other,,
1980,1009897,1,3,,103188875,2157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Deposit; Study_ID: R020910",Other,,
1981,1009898,1,3,,103188875,2157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Dilatation; Study_ID: R020910",Other,,
1982,1009899,1,3,,103188875,2157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Hyaline Droplets; Study_ID: R020910",Other,,
1983,1009900,1,3,,103188875,2157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Necrosis; Study_ID: R020910",Other,,
1984,1009901,1,3,,103188875,2157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Endocardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: R020910",Other,,
1985,1009902,1,3,,103188875,2157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Tunica Media, Hypertrophy; Study_ID: R020910",Other,,
1986,1009903,1,3,,103188875,2157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Cyst(S); Study_ID: R020910",Other,,
1987,1009904,1,3,,103188875,2157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Myocyte, Degeneration; Study_ID: R020910",Other,,
1988,1009905,1,3,,103188875,2157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: R020910",Other,,
1989,1009906,1,3,,103188875,2157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Cyst(S); Study_ID: R020910",Other,,
1990,1009907,1,3,,103188875,2157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Regeneration; Study_ID: R020910",Other,,
1991,1009908,1,3,,103188875,2157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mixed Cell; Study_ID: R020910",Other,,
1992,1009909,1,3,,103188875,2157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Fibrosis; Study_ID: R020910",Other,,
1993,1009910,1,3,,103188875,2157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Myocyte, Degeneration; Study_ID: R020910",Other,,
1994,1009911,1,3,,103188875,2157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: R020910",Other,,
1995,1009912,1,3,,103188875,2157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Cast, Proteinaceous; Study_ID: R020910",Other,,
1996,1011746,1,3,,103188875,2157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mixed Cell; Study_ID: R020910",Other,,
1997,1012330,1,3,,103188875,2157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: R020910",Other,,
1998,1012331,1,3,,103188875,2157,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Autolysis; Study_ID: R020910,Other,,
1999,1012332,1,3,,103188875,2157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Fibrosis; Study_ID: R020910",Other,,
2000,1012333,1,3,,103188875,2157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Myocyte, Degeneration; Study_ID: R020910",Other,,
2001,1012334,1,3,,103188875,2157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: R020910",Other,,
2002,1012335,1,3,,103188875,2157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Polymorphonuclear Cell; Study_ID: R020910",Other,,
2003,1012336,1,3,,103188875,2157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Mononuclear Cell; Study_ID: R020910",Other,,
2004,1012337,1,3,,103188875,2157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Mineralization; Study_ID: R020910",Other,,
2005,1012338,1,3,,103188875,2157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Tubule, Regeneration; Study_ID: R020910",Other,,
2006,1012339,1,3,,103188875,2157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Fibrosis; Study_ID: R020910",Other,,
2007,1012340,1,3,,103188875,2157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Tubule, Dilatation; Study_ID: R020910",Other,,
2008,1012341,1,3,,103188875,2157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mixed Cell; Study_ID: R020910",Other,,
2009,1012342,1,3,,103188875,2157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: R020910",Other,,
2010,1012343,1,3,,103188875,2157,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Degeneration; Study_ID: R020910",Other,,
2011,1048973,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 634/11,Other,,
2012,1048974,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 634/11,Other,,
2013,1048975,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 634/11,Other,,
2014,1048976,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 634/12,Other,,
2015,1048977,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 634/12,Other,,
2016,1048978,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 634/12,Other,,
2017,1048979,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 634/12,Other,,
2018,1048980,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 634/12,Other,,
2019,1048981,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 634/13,Other,,
2020,1048982,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 634/13,Other,,
2021,1048983,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 634/13,Other,,
2022,1048984,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 634/13,Other,,
2023,1048985,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 634/13,Other,,
2024,1048986,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 634/14,Other,,
2025,1048987,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 634/14,Other,,
2026,1048988,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 634/14,Other,,
2027,1048989,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 634/14,Other,,
2028,1048990,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 634/14,Other,,
2029,1048991,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 634/15,Other,,
2030,1048992,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 634/15,Other,,
2031,1048993,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 634/15,Other,,
2032,1048994,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 634/15,Other,,
2033,1048995,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 634/15,Other,,
2034,1048996,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 634/16,Other,,
2035,1048997,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 634/16,Other,,
2036,1048998,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 634/16,Other,,
2037,1048999,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 634/16,Other,,
2038,1049000,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 634/16,Other,,
2039,1050747,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 209/5,Other,,
2040,1050748,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 209/5,Other,,
2041,1050749,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 209/5,Other,,
2042,1050750,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 209/5,Other,,
2043,1050751,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 209/5,Other,,
2044,1050752,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 209/6,Other,,
2045,1050753,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 209/6,Other,,
2046,1050754,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 209/6,Other,,
2047,1050755,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 209/6,Other,,
2048,1050756,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 209/6,Other,,
2049,1050757,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 209/7,Other,,
2050,1050758,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 209/7,Other,,
2051,1050759,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 209/7,Other,,
2052,1051010,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 209/7,Other,,
2053,1051011,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 209/7,Other,,
2054,1051012,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 209/8,Other,,
2055,1051013,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 209/8,Other,,
2056,1051014,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 209/8,Other,,
2057,1051015,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 209/8,Other,,
2058,1051016,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 209/8,Other,,
2059,1051017,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 209/9,Other,,
2060,1051018,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 209/9,Other,,
2061,1051019,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 209/9,Other,,
2062,1051020,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 209/9,Other,,
2063,1051021,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 209/9,Other,,
2064,1051022,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 209/10,Other,,
2065,1051023,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 209/10,Other,,
2066,1051024,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 209/10,Other,,
2067,1051025,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 209/10,Other,,
2068,1051026,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 209/10,Other,,
2069,1051027,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 209/11,Other,,
2070,1051028,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 209/11,Other,,
2071,1051029,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 209/11,Other,,
2072,1051030,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 209/11,Other,,
2073,1051031,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 209/11,Other,,
2074,1051032,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 209/12,Other,,
2075,1051033,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 209/12,Other,,
2076,1051034,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 209/12,Other,,
2077,1051035,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 209/12,Other,,
2078,1051036,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 209/12,Other,,
2079,1051037,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 209/13,Other,,
2080,1051038,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 209/13,Other,,
2081,1051771,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 209/13,Other,,
2082,1051772,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 209/13,Other,,
2083,1051773,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 4 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 209/13,Other,,
2084,1051774,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 209/14,Other,,
2085,1051775,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 209/14,Other,,
2086,1051776,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 209/14,Other,,
2087,1051777,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 209/14,Other,,
2088,1051778,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 8 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 209/14,Other,,
2089,1051779,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 209/15,Other,,
2090,1051780,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 209/15,Other,,
2091,1052042,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 209/15,Other,,
2092,1052043,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 209/15,Other,,
2093,1052044,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 15 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 209/15,Other,,
2094,1052045,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 209/16,Other,,
2095,1052046,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 209/16,Other,,
2096,1052047,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 209/16,Other,,
2097,1052048,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 209/16,Other,,
2098,1052049,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Daily Repeat; Time: 29 day; Dose: High; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 209/16,Other,,
2099,1052050,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 634/5,Other,,
2100,1052051,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 634/5,Other,,
2101,1052052,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 634/5,Other,,
2102,1052053,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 634/5,Other,,
2103,1052054,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 634/5,Other,,
2104,1052055,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 634/6,Other,,
2105,1052056,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 634/6,Other,,
2106,1052057,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 634/6,Other,,
2107,1052058,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 634/6,Other,,
2108,1052059,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 634/6,Other,,
2109,1052060,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 634/7,Other,,
2110,1052061,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 634/7,Other,,
2111,1052062,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 634/7,Other,,
2112,1052063,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 634/7,Other,,
2113,1052064,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 634/7,Other,,
2114,1052065,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 634/8,Other,,
2115,1052066,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 634/8,Other,,
2116,1052067,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 634/8,Other,,
2117,1052068,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 634/8,Other,,
2118,1052069,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 24 hr; Dose: Low; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 634/8,Other,,
2119,1052070,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 634/9,Other,,
2120,1052071,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 634/9,Other,,
2121,1052072,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 634/9,Other,,
2122,1052073,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 634/9,Other,,
2123,1052074,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 3 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 634/9,Other,,
2124,1052075,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 634/10,Other,,
2125,1052076,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 634/10,Other,,
2126,1052077,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Total Kidney Weight); Study_ID: 634/10,Other,,
2127,1052078,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Right Kidney Weight); Study_ID: 634/10,Other,,
2128,1052834,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 6 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Left Kidney Weight); Study_ID: 634/10,Other,,
2129,1052835,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: TERMBW (Terminal Body Weight); Study_ID: 634/11,Other,,
2130,1052836,1,2,,103188875,2157,Unspecified,,,,,Open TG-GATES: Regimen: Single; Time: 9 hr; Dose: Middle; Route: Gavage | Dataset: Organ Weight; Assay: WEIGHT (Liver Weight); Study_ID: 634/11,Other,,
2131,1057862,1,1,,103188875,2157,Unspecified,,,10.0,EC50,Inhibition of RML prion protein infected in mouse dividing ScN2a-cl3 cells expressing full length mouse PrP assessed as reduction of PrPsc level after 5 days by ELISA,Confirmatory,24183589.0,
2132,1057863,1,1,,103188875,2157,Unspecified,,,10.0,LC50,Cytotoxicity against mouse dividing ScN2a-cl3 cells assessed as cell viability after 5 days by calcein-AM staining-based fluorescence assay,Confirmatory,24183589.0,
2133,1057864,1,1,,103188875,2157,Inconclusive,,,,,Ratio of LC50 for dividing mouse ScN2a-cl3 cells to EC50 for inhibition of RML prion protein,Other,24183589.0,
2134,1079931,1,1,,103188875,2157,Unspecified,,,,,"Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]",Other,15646539.0,
2135,1079932,1,1,,103188875,2157,Unspecified,,,,,"Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]",Other,15646539.0,
2136,1079933,1,1,,103188875,2157,Unspecified,,,,,"Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is number of references indexed. [column 'AIGUE' in source]",Other,15646539.0,
2137,1079934,1,1,,103188875,2157,Unspecified,,,,,"Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]",Other,15646539.0,
2138,1079935,1,1,,103188875,2157,Unspecified,,,,,"Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]",Other,15646539.0,
2139,1079936,1,1,,103188875,2157,Unspecified,,,,,"Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]",Other,15646539.0,
2140,1079937,1,1,,103188875,2157,Unspecified,,,,,"Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]",Other,15646539.0,
2141,1079938,1,1,,103188875,2157,Unspecified,,,,,"Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]",Other,15646539.0,
2142,1079939,1,1,,103188875,2157,Unspecified,,,,,"Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]",Other,15646539.0,
2143,1079940,1,1,,103188875,2157,Unspecified,,,,,"Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]",Other,15646539.0,
2144,1079941,1,1,,103188875,2157,Unspecified,,,,,"Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]",Other,15646539.0,
2145,1079942,1,1,,103188875,2157,Unspecified,,,,,"Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]",Other,15646539.0,
2146,1079943,1,1,,103188875,2157,Unspecified,,,,,"Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]",Other,15646539.0,
2147,1079944,1,1,,103188875,2157,Unspecified,,,,,"Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]",Other,15646539.0,
2148,1079945,1,1,,103188875,2157,Unspecified,,,,,Animal toxicity known. [column 'TOXIC' in source],Other,15646539.0,
2149,1079946,1,1,,103188875,2157,Unspecified,,,,,Presence of at least one case with successful reintroduction. [column 'REINT' in source],Other,15646539.0,
2150,1079947,1,1,,103188875,2157,Unspecified,,,,,Comments (NB not yet translated). [column 'COMMENTAIRES' in source],Other,15646539.0,
2151,1079948,1,1,,103188875,2157,Unspecified,,,,,"Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]",Other,15646539.0,
2152,1079949,1,1,,103188875,2157,Unspecified,,,,,Proposed mechanism(s) of liver damage. [column 'MEC' in source],Other,15646539.0,
2153,1117298,1,2,,170464920,2157,Inactive,,,2.5119,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 green channel",Confirmatory,,
2154,1117301,1,2,,170464920,2157,Active,,,6.3096,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 blue channel",Confirmatory,,
2155,1117302,1,2,,170464920,2157,Inactive,,,0.7079,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen1 green channel",Confirmatory,,
2156,1117303,1,2,,170464920,2157,Active,,,6.31,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 1 ratio channel",Confirmatory,,
2157,1117304,1,2,,170464920,2157,Active,,,3.5481,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel",Confirmatory,,
2158,1117305,1,2,,170464920,2157,Active,,,2.8184,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel",Confirmatory,,
2159,1117310,1,1,,170464920,2157,Inactive,,,2.51189,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, green channel",Confirmatory,,
2160,1117311,1,1,,170464920,2157,Inactive,,,6.30957,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, blue channel",Confirmatory,,
2161,1117312,1,1,,170464920,2157,Active,,,2.81838,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel",Confirmatory,,
2162,1117314,1,1,,170464920,2157,Inactive,,,3.5481300000000005,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, blue channel",Confirmatory,,
2163,1117315,1,1,,170464920,2157,Inactive,,,0.707946,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, green channel",Confirmatory,,
2164,1117318,1,1,,170464920,2157,Active,,,6.30957,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen1, ratio channel",Confirmatory,,
2165,1117324,1,1,,170464920,2157,Inactive,,,10.0,IC50,VEGF stimulated ADSC/ECFC co-culture nuclear area decrease (viability)-IC50,Confirmatory,,
2166,1117325,1,1,,170464920,2157,Inactive,,,6.8806,IC50,nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-IC50,Confirmatory,,
2167,1117326,1,1,,170464920,2157,Active,,,,,nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-screen,Screening,,
2168,1117327,1,1,,170464920,2157,Inactive,,,20.0,IC50,alkaline phosphatase stimulation in WNT3A conditioned C2C12 cells-IC50,Confirmatory,,
2169,1117328,1,1,,170464920,2157,Inactive,,,,,human p70S6K1 kinase inhibition-screen,Screening,,
2170,1117329,1,1,,170464920,2157,Inactive,,,,,insulin secretion from INS-1E cells in the presence of 5 mM glucose-screen,Screening,,
2171,1117336,1,1,,170464920,2157,Active,,,,,GSK3B-pretreated HCT116 viability from Cell TiterGlo-screen,Screening,,
2172,1117337,1,1,,170464920,2157,Inactive,,,10.0,IC50,VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-IC50,Confirmatory,,
2173,1117340,1,1,,170464920,2157,Active,,,,,VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-screen,Screening,,
2174,1117341,1,1,,170464920,2157,Inactive,,,,,GLP1 secretion from NCI-H716 cells-screen,Screening,,
2175,1117342,1,1,,170464920,2157,Active,,,,,HCT116 viability from Cell TiterGlo-screen,Screening,,
2176,1117343,1,1,,170464920,2157,Active,,,,,SW480 viability from Cell TiterGlo-screen,Screening,,
2177,1117346,1,1,,170464920,2157,Active,,,,,DLD-1 viability from Cell TiterGlo-screen,Screening,,
2178,1117347,1,1,,170464920,2157,Inactive,,,10.0,IC50,Decreased HeLa cell count-IC50,Confirmatory,,
2179,1117349,1,1,,170464920,2157,Inactive,,,10.0,IC50,Increased HeLa cells with 2N DNA content-IC50,Confirmatory,,
2180,1117350,1,1,,170464920,2157,Inactive,,,10.0,IC50,Increased chromatin condensation in HeLa cells-IC50,Confirmatory,,
2181,1117351,1,1,,170464920,2157,Inactive,,,10.0,IC50,Increased HeLa cells with 4N DNA content-IC50,Confirmatory,,
2182,1117353,1,1,,170464920,2157,Inactive,,,,,human KDR kinase inhibition-screen,Screening,,
2183,1117354,1,1,,170464920,2157,Inactive,,,,,human JAK2 kinase inhibition-screen,Screening,,
2184,1117355,1,1,,170464920,2157,Inactive,,,,,human GSK3B kinase inhibition-screen,Screening,,
2185,1117356,1,1,,170464920,2157,Inactive,,,,,human FLT3 kinase inhibition-screen,Screening,,
2186,1159394,1,2,,103188875,2157,Unspecified,,,,,"ASTRAZENECA: Intrinsic clearance measured in human liver microsomes following incubation at 37C. Experimental range <3 to >150 microL/min/mg. Rapid Commun. Mass Spectrom. 2010, 24, 1730-1736.",Other,,
2187,1159395,1,2,,103188875,2157,Unspecified,,,,,"ASTRAZENECA: Intrinsic clearance measured in rat hepatocytes following incubation at 37C. Experimental range <3 to >150 microL/min/1E6 cells. Rapid Commun. Mass Spectrom. 2010, 24, 1730-1736",Other,,
2188,1159509,1,1,,170464920,2157,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
2189,1159515,1,1,,170464920,2157,Active,,,26.8325,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
2190,1159516,1,1,,170464920,2157,Inactive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
2191,1159517,1,1,,170464920,2157,Inconclusive,,,23.9145,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
2192,1159518,1,1,,170464920,2157,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
2193,1159519,1,1,,170464920,2157,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
2194,1159520,1,1,,170464920,2157,Inconclusive,,,33.4915,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
2195,1159521,1,1,,170464920,2157,Active,15928672.0,19885.0,26.6032,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
2196,1159523,1,1,,170464920,2157,Inconclusive,15928672.0,19885.0,26.6032,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
2197,1159524,1,1,,124879287,2157,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
2198,1159525,1,1,,170464920,2157,Inconclusive,,,18.9959,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
2199,1159526,1,1,,170464920,2157,Inconclusive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
2200,1159527,1,1,,170464920,2157,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
2201,1159528,1,1,,170464920,2157,Inconclusive,119627033.0,3725.0,6.00704,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
2202,1159529,1,1,,170464920,2157,Active,,,16.9301,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
2203,1159531,1,1,,170464920,2157,Inconclusive,325495497.0,6256.0,8.48517,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
2204,1159551,1,1,,170464920,2157,Inconclusive,,,29.8493,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
2205,1159552,1,1,,170464920,2157,Active,325495463.0,5914.0,26.6032,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
2206,1159553,2,1,,170464920,2157,Inconclusive,325495463.0,5914.0,29.8493,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
2207,1159555,1,1,,170464920,2157,Inconclusive,325495463.0,5914.0,26.6032,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
2208,1159580,2,1,,273002715,2157,Inconclusive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
2209,1159580,2,1,,273003149,2157,Active,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
2210,1159607,2,1,,312309783,2157,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
2211,1159614,1,2,,170464920,2157,Inactive,22328079.0,2581.0,,Potency,A Novel Cell-Based Assay to Identify Small Molecules for B -Galactocerebrosidase,Confirmatory,,
2212,1161942,1,1,,103188875,2157,Unspecified,,,,,Hepatotoxicity in zebrafish embryo at 30 uM incubated until 7 days post fertilization,Other,25168747.0,
2213,1184068,1,2,,103188875,2157,Inconclusive,123948.0,3620.0,,IC50,Inhibition of IDO1 (unknown origin) using L-tryptophan substrate incubated for 60 mins by HPLC,Confirmatory,25036789.0,
2214,1184074,1,1,,103188875,2157,Active,,,,,Solubility of the compound in pH 6.5 phosphate buffer containing 5% DMSO,Other,25036789.0,
2215,1184075,1,2,,103188875,2157,Unspecified,123948.0,3620.0,,,Inhibition of IDO1 (unknown origin) at highest soluble concentration using L-tryptophan substrate incubated for 60 mins by HPLC,Other,25036789.0,
2216,1196039,1,1,,103188875,2157,Unspecified,,,,,Cytotoxicity against human HepG2 cells assessed as reduction in cell viability after 24 hrs by Neutral red uptake assay,Other,25544686.0,
2217,1196042,1,1,,103188875,2157,Unspecified,,,,,Cytotoxicity against human HepG2 cells assessed as reduction in cell viability at >= 10 uM after 24 hrs by Neutral red uptake assay,Other,25544686.0,
2218,1196044,1,1,,103188875,2157,Unspecified,,,,,Cytotoxicity against human HepG2 cells assessed as disruption of membrane integrity at >= 50 uM after 24 hrs by LDH release assay,Other,25544686.0,
2219,1196046,1,1,,103188875,2157,Unspecified,,,,,Cytotoxicity against human HepG2 cells assessed as NBD-PC phospholipid accumulation after 24 hrs by Hoechst 33342 normalization-based fluorescence assay,Other,25544686.0,
2220,1196047,1,1,,103188875,2157,Unspecified,,,,,Cytotoxicity against human HepG2 cells assessed as NBD-PC phospholipid accumulation at 10 uM after 24 hrs by Hoechst 33342 normalization-based fluorescence assay relative to control,Other,25544686.0,
2221,1196048,1,1,,103188875,2157,Unspecified,,,,,Cytotoxicity against human HepG2 cells at 100 uM after 24 hrs by Hoechst 33342 staining-based fluorescence assay,Other,25544686.0,
2222,1196052,1,1,,103188875,2157,Unspecified,,,,,Cytotoxicity against human HepG2 cells assessed as increase in lysosomal beta-hexosaminidase level at 50 to 100 uM after 24 hrs by MUG-based fluorescence assay,Other,25544686.0,
2223,1196058,1,1,,103188875,2157,Unspecified,,,,,Cytotoxicity against human HepG2 cells assessed as formation of lysosomal inclusion bodies at 10 uM after 24 hrs by transmission electron microscopy,Other,25544686.0,
2224,1207147,1,1,,103188875,2157,Active,,,4.8,IC50,Inhibition of Na channel (species unknown),Confirmatory,21300721.0,
2225,1207178,1,1,,103188875,2157,Active,,,0.27,IC50,Inhibition of voltage-gated L-type Ca channel (species unknown),Confirmatory,21300721.0,
2226,1207206,1,2,,103188875,2157,Active,7531135.0,3757.0,0.03,IC50,Inhibition of potassium current (Ikr) measured using whole-cell patch clamp experiments in HEK-293 cells stable transfected with hERG cDNA,Confirmatory,21300721.0,
2227,1207237,1,2,,103188875,2157,Active,,,,,Effective free therapeutic plasma concentration (EFTPC): the concentration of unbound compund in the blood plasma at therapeutic dose (mean of range),Other,21300721.0,
2228,1207726,1,1,,103188875,2157,Active,,,1.9,IC50,"Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits",Confirmatory,23812503.0,
2229,1209975,1,2,,103188875,2157,Unspecified,117144.0,1544.0,,,Inhibition of CYP1A2-mediated phenacetin metabolite formation in human liver microsomes at 5 uM after 8 mins by LC-MS/MS analysis relative to control,Other,22328583.0,
2230,1209977,1,2,,103188875,2157,Unspecified,117225.0,1558.0,,,Inhibition of CYP2C8-mediated paclitaxel metabolite formation in human liver microsomes at 5 uM after 8 mins by LC-MS/MS analysis relative to control,Other,22328583.0,
2231,1209979,1,2,,103188875,2157,Unspecified,6686268.0,1559.0,,,Inhibition of CYP2C9-mediated diclofenac metabolite formation in human liver microsomes at 5 uM after 8 mins by LC-MS/MS analysis relative to control,Other,22328583.0,
2232,1209981,1,2,,103188875,2157,Unspecified,60416369.0,1557.0,,,Inhibition of CYP2C19-mediated S-mephenytoin metabolite formation in human liver microsomes at 5 uM after 8 mins by LC-MS/MS analysis relative to control,Other,22328583.0,
2233,1209983,1,2,,103188875,2157,Unspecified,84028191.0,1565.0,,,Inhibition of CYP2D6-mediated dextromethorphan metabolite formation in human liver microsomes at 5 uM after 8 mins by LC-MS/MS analysis relative to control,Other,22328583.0,
2234,1209985,1,2,,103188875,2157,Unspecified,116241312.0,1576.0,,,Inhibition of CYP3A4-mediated midazolam metabolite formation in human liver microsomes at 5 uM after 8 mins by LC-MS/MS analysis relative to control,Other,22328583.0,
2235,1209994,1,2,,103188875,2157,Unspecified,21264413.0,1573.0,,,Drug metabolism in human liver microsomes assessed as CYP2J2-mediated 4-hydroxyamiodarone formation at 1 uM after 5 to 45 mins by LC-MS/MS analysis,Other,22328583.0,
2236,1209995,1,2,,103188875,2157,Unspecified,117144.0,1544.0,,,Drug metabolism assessed as recombinant CYP1A2 (unknown origin)-mediated 4-hydroxyamiodarone formation at 1 uM after 5 to 45 mins by LC-MS/MS analysis,Other,22328583.0,
2237,1209996,1,2,,103188875,2157,Unspecified,117205.0,1555.0,,,Drug metabolism assessed as recombinant CYP2B6 (unknown origin)-mediated 4-hydroxyamiodarone formation at 1 uM after 5 to 45 mins by LC-MS/MS analysis,Other,22328583.0,
2238,1209997,1,2,,103188875,2157,Unspecified,117225.0,1558.0,,,Drug metabolism assessed as recombinant CYP2C8 (unknown origin)-mediated 4-hydroxyamiodarone formation at 1 uM after 5 to 45 mins by LC-MS/MS analysis,Other,22328583.0,
2239,1209998,1,2,,103188875,2157,Unspecified,6686268.0,1559.0,,,Drug metabolism assessed as recombinant CYP2C9 (unknown origin)-mediated 4-hydroxyamiodarone formation at 1 uM after 5 to 45 mins by LC-MS/MS analysis,Other,22328583.0,
2240,1209999,1,2,,103188875,2157,Unspecified,60416369.0,1557.0,,,Drug metabolism assessed as recombinant CYP2C19 (unknown origin)-mediated 4-hydroxyamiodarone formation at 1 uM after 5 to 45 mins by LC-MS/MS analysis,Other,22328583.0,
2241,1210000,1,2,,103188875,2157,Unspecified,84028191.0,1565.0,,,Drug metabolism assessed as recombinant CYP2D6 (unknown origin)-mediated 4-hydroxyamiodarone formation at 1 uM after 5 to 45 mins by LC-MS/MS analysis,Other,22328583.0,
2242,1210001,1,2,,103188875,2157,Unspecified,117250.0,1571.0,,,Drug metabolism assessed as recombinant CYP2E1 (unknown origin)-mediated 4-hydroxyamiodarone formation at 1 uM after 5 to 45 mins by LC-MS/MS analysis,Other,22328583.0,
2243,1210002,1,2,,103188875,2157,Unspecified,21264413.0,1573.0,,,Drug metabolism assessed as recombinant CYP2J2 (unknown origin)-mediated 4-hydroxyamiodarone formation at 1 uM after 20 mins by LC-MS/MS analysis,Other,22328583.0,
2244,1210003,1,2,,103188875,2157,Unspecified,116241312.0,1576.0,,,Drug metabolism assessed as recombinant CYP3A4 (unknown origin)-mediated 4-hydroxyamiodarone formation at 1 uM after 5 to 45 mins by LC-MS/MS analysis,Other,22328583.0,
2245,1210004,1,2,,103188875,2157,Unspecified,117157.0,1577.0,,,Drug metabolism assessed as recombinant CYP3A5 (unknown origin)-mediated 4-hydroxyamiodarone formation at 1 uM after 5 to 45 mins by LC-MS/MS analysis,Other,22328583.0,
2246,1210007,1,2,,103188875,2157,Unspecified,21264413.0,1573.0,,,Drug metabolism assessed as recombinant CYP2J2 (unknown origin)-mediated 3-hydroxyamiodarone formation at 1 uM after 5 to 45 mins by LC-MS/MS analysis,Other,22328583.0,
2247,1210008,1,2,,103188875,2157,Unspecified,116241312.0,1576.0,,,Drug metabolism assessed as recombinant CYP3A4 (unknown origin)-mediated 3-hydroxyamiodarone formation at 1 uM after 5 to 45 mins by LC-MS/MS analysis,Other,22328583.0,
2248,1210010,1,2,,103188875,2157,Unspecified,21264413.0,1573.0,,,Drug metabolism in human liver microsomes assessed as CYP2J2-mediated 3-hydroxyamiodarone formation at 1 uM after 5 to 45 mins by LC-MS/MS analysis,Other,22328583.0,
2249,1210012,1,2,,103188875,2157,Unspecified,21264413.0,1573.0,,,Drug metabolism in human liver microsomes assessed as CYP2J2-mediated 4-hydroxyamiodarone formation measured per pmol protein at 5 uM after 20 mins by LC-MS/MS analysis,Other,22328583.0,
2250,1210013,1,2,,103188875,2157,Unspecified,21264413.0,1573.0,,,Inhibition of recombinant CYP2J2 (unknown origin)-mediated terfenadine hydroxylation assessed as remaining activity at 30 uM after 5 mins by LC-MS analysis relative to control,Other,22328583.0,
2251,1210014,1,2,,103188875,2157,Unspecified,21264413.0,1573.0,,,Inhibition of recombinant CYP2J2 (unknown origin)-mediated astemizole O-demethylation assessed as remaining activity at 30 uM after 5 mins by LC-MS/MS analysis relative to control,Other,22328583.0,
2252,1222793,1,1,,103188875,2157,Unspecified,,,,,"Dissociation constant, pKa of the compound",Other,23454828.0,
2253,1224824,1,1,,124879289,2157,Inactive,,,10.4904,Potency,High-throughput drug toxicity screening in the BPDCN cell line Gen2.2,Confirmatory,,
2254,1224825,1,1,,124879289,2157,Inactive,,,,Potency,High-throughput drug toxicity screening in the BPDCN cell line Cal-1,Confirmatory,,
2255,1224834,3,1,,170464920,2157,Active,,,29.8493,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
2256,1224835,1,1,,170464920,2157,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
2257,1224836,1,1,,170464920,2157,Inconclusive,,,29.8493,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
2258,1224837,1,1,,170464920,2157,Inconclusive,,,29.8493,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
2259,1224838,1,1,,170464920,2157,Inactive,66775687.0,9970.0,11.8832,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
2260,1224839,1,1,,170464920,2157,Inactive,66775687.0,9970.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
2261,1224840,3,1,,170464920,2157,Inconclusive,,,26.6032,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
2262,1224841,3,1,,170464920,2157,Inconclusive,325495545.0,2101.0,29.8493,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
2263,1224842,3,1,,170464920,2157,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
2264,1224843,1,1,,170464920,2157,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
2265,1224844,1,1,,170464920,2157,Active,,,21.3138,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
2266,1224845,1,1,,170464920,2157,Inconclusive,344243002.0,100757539.0,61.9315,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
2267,1224846,1,1,,170464920,2157,Inconclusive,11995455.0,3091.0,26.8325,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
2268,1224847,1,1,,170464920,2157,Active,,,43.8442,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
2269,1224848,3,1,,170464920,2157,Active,325495545.0,2101.0,29.8493,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
2270,1224849,3,1,,170464920,2157,Inactive,325495545.0,2101.0,26.6032,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
2271,1224857,2,1,,124879289,2157,Inconclusive,,,37.2212,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
2272,1224857,2,1,,170464920,2157,Inactive,,,7.0795,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
2273,1224859,2,1,,90341282,2157,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
2274,1224859,2,1,,124879289,2157,Inactive,,,11.7704,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
2275,1224859,2,1,,170464920,2157,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
2276,1224863,1,1,,176483944,2157,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
2277,1224863,1,1,,316919575,2157,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
2278,1224867,1,1,,170464920,2157,Active,,,23.9145,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
2279,1224868,1,1,,170464920,2157,Active,,,23.9145,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
2280,1224869,1,1,,170464920,2157,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
2281,1224870,1,1,,170464920,2157,Inconclusive,,,26.8325,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
2282,1224871,1,1,,170464920,2157,Inconclusive,,,26.8325,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
2283,1224872,1,1,,170464920,2157,Active,,,21.3138,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
2284,1224873,1,1,,170464920,2157,Inconclusive,,,26.8325,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
2285,1224874,1,1,,170464920,2157,Active,,,23.9145,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
2286,1224875,1,1,,170464920,2157,Inconclusive,,,26.8325,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
2287,1224876,1,1,,170464920,2157,Inconclusive,,,26.8325,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
2288,1224877,1,1,,170464920,2157,Active,,,23.9145,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
2289,1224878,1,1,,170464920,2157,Inconclusive,,,26.8325,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
2290,1224879,1,1,,170464920,2157,Active,,,26.8325,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
2291,1224880,1,1,,170464920,2157,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
2292,1224881,1,1,,170464920,2157,Inconclusive,,,26.8325,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
2293,1224882,1,1,,170464920,2157,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
2294,1224883,1,1,,170464920,2157,Active,,,26.8325,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
2295,1224884,1,1,,170464920,2157,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
2296,1224885,1,1,,170464920,2157,Inconclusive,,,23.9145,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
2297,1224886,1,1,,170464920,2157,Active,,,23.9145,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
2298,1224887,1,1,,170464920,2157,Inconclusive,,,23.9145,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
2299,1224888,1,1,,170464920,2157,Inconclusive,,,26.8325,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
2300,1224889,1,1,,170464920,2157,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
2301,1224890,1,1,,170464920,2157,Inconclusive,,,26.8325,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
2302,1224892,1,1,,170464920,2157,Inactive,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
2303,1224893,1,1,,170464920,2157,Inconclusive,66775687.0,9970.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
2304,1224894,1,1,,170464920,2157,Inconclusive,11995455.0,3091.0,26.8325,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
2305,1224895,1,1,,170464920,2157,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
2306,1224896,1,1,,170464920,2157,Active,344243002.0,100757539.0,59.5998,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
2307,1224905,2,1,,92308723,2157,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
2308,1224905,2,1,,92308723,2157,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
2309,1232164,1,1,,103188875,2157,Unspecified,,,,,Fraction unbound in human plasma at pH 7.4 after 18 hrs by equilibrium dialysis,Other,,
2310,1232165,1,1,,103188875,2157,Unspecified,,,,,Fraction unbound in dog plasma at pH 7.4 after 18 hrs by equilibrium dialysis,Other,,
2311,1259241,1,1,,170464920,2157,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
2312,1259242,1,1,,170464920,2157,Inconclusive,,,29.8493,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
2313,1259243,1,1,,170464920,2157,Inconclusive,124375976.0,367.0,29.8493,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
2314,1259244,1,1,,170464920,2157,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
2315,1259247,1,1,,170464920,2157,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
2316,1259248,1,1,,170464920,2157,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
2317,1259252,1,1,,124879289,2157,Active,169655958.0,,8.3328,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (RDES),Confirmatory,,
2318,1259253,1,1,,124879289,2157,Active,169655958.0,,8.3328,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC71),Confirmatory,,
2319,1259255,1,1,,124879289,2157,Active,169655958.0,,9.3495,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (EW8),Confirmatory,,
2320,1259256,1,1,,124879289,2157,Active,169655958.0,,8.3328,Potency,qHTS Screen of the MIPE 4.0 Collection Against Ewings Sarcoma (TC32),Confirmatory,,
2321,1259325,1,2,,336954224,2157,Inactive,4504843.0,3763.0,,,Discovering small molecule activators of G protein-gated inwardly-rectifying potassium subunit 2 (GIRK2) containing channels utilizing methyl-2 4-pentanediol (MPD) for partial channel activation during screening,Screening,,
2322,1259344,1,1,,144203634,2157,Active,,,10.0,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
2323,1259355,1,1,,26751596,2157,Inconclusive,,,1.7783,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-1,Confirmatory,,
2324,1259356,1,1,,144203634,2157,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-2,Confirmatory,,
2325,1259364,1,1,,170464920,2157,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
2326,1259365,1,1,,170464920,2157,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
2327,1259366,1,1,,170464920,2157,Inconclusive,,,33.4915,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
2328,1259367,1,1,,170464920,2157,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
2329,1259368,1,1,,170464920,2157,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
2330,1259369,1,1,,170464920,2157,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
2331,1259377,1,1,,170464920,2157,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
2332,1259378,1,1,,170464920,2157,Active,54288833.0,2100.0,26.6032,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
2333,1259379,1,1,,170464920,2157,Active,,,33.4915,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
2334,1259380,1,1,,170464920,2157,Active,,,29.8493,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
2335,1259381,1,1,,170464920,2157,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
2336,1259382,1,1,,170464920,2157,Active,,,26.6032,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
2337,1259383,1,1,,170464920,2157,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
2338,1259384,1,1,,170464920,2157,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
2339,1259385,1,1,,170464920,2157,Inconclusive,119601739.0,7253.0,29.8493,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
2340,1259386,1,1,,170464920,2157,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
2341,1259387,1,1,,170464920,2157,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
2342,1259388,1,1,,170464920,2157,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
2343,1259390,1,1,,170464920,2157,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
2344,1259391,1,1,,170464920,2157,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
2345,1259392,1,1,,170464920,2157,Inactive,109731339.0,2737.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
2346,1259393,1,1,,170464920,2157,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
2347,1259394,1,1,,170464920,2157,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
2348,1259395,1,1,,170464920,2157,Inconclusive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
2349,1259396,1,1,,170464920,2157,Inconclusive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
2350,1259400,1,1,,170464920,2157,Inactive,166209887.0,59350.0,,,qHTS Assay for Antagonists of the Relaxin Receptor RXFP1,Screening,,
2351,1259401,1,1,,170464920,2157,Inconclusive,325495545.0,2101.0,6.68242,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
2352,1259402,1,1,,170464920,2157,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
2353,1259403,1,1,,170464920,2157,Inconclusive,325495545.0,2101.0,27.644000000000002,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
2354,1259404,1,1,,170464920,2157,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
2355,1259407,1,1,,363907306,2157,Active,,,,,CCRIS mutagenicity studies,Other,,
2356,1259416,1,2,,340079488,2157,Active,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
2357,1259416,1,2,,375177940,2157,Active,56786138.0,3458.0,,,Toxoplasma gondii inhibition HTS in the presence of IFN-y,Screening,,
2358,1259421,1,1,,340079488,2157,Inactive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
2359,1259421,1,1,,375177940,2157,Inconclusive,56786138.0,3458.0,,,Toxoplasma gondii HTS in the absence of IFN-y,Screening,,
2360,1259423,1,2,,354772536,2157,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
2361,1259423,1,2,,354914253,2157,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
2362,1259423,1,2,,354921948,2157,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
2363,1259423,1,2,,354998978,2157,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
